Organization and Basis of Presentation [Abstract]

Issuance value per share of no-par value, nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.

+ References+ Details

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
REVENUES:
License fees	$ 2,218,174	$ 899,998	$ 263,757
Royalties from product sales	366,775	541,681	756,950
Grant income	1,573,329	2,222,458	2,767,181
Sale of research products	276,058	251,190	646,271
Total revenues	4,434,336	3,915,327	4,434,159
Cost of sales	(792,659)	(434,271)	(79,397)
Total revenues, net	3,641,677	3,481,056	4,354,762
EXPENSES:
Research and development	(26,609,423)	(18,116,688)	(13,699,691)
Acquired in-process research and development	(17,458,766)	0	0
General and administrative	(15,558,674)	(10,365,045)	(9,341,502)
Total expenses	(59,626,863)	(28,481,733)	(23,041,193)
Loss from operations	(55,985,186)	(25,000,677)	(18,686,431)
OTHER INCOME (EXPENSES):
Interest income/(expense), net	(578)	19,383	29,727
Gain/(loss) on sale of fixed assets	5,120	(6,856)	(6,246)
Other income/(expense), net	(209,177)	(317,710)	219,067
Total other income/(expenses), net	(204,635)	(305,183)	242,548
DEFERRED NET LOSS BEFORE INCOME TAX BENEFITS	(56,189,821)	(25,305,860)	(18,443,883)
Deferred income tax benefit	3,280,695	0	0
NET LOSS	(52,909,126)	(25,305,860)	(18,443,883)
Net loss attributable to the noncontrolling interest	9,026,291	3,880,157	1,928,383
NET LOSS ATTRIBUTABLE TO BIOTIME, INC.	(43,882,835)	(21,425,703)	(16,515,500)
Foreign currency translation gain/(loss)	119,469	63,179	(1,020,087)
Unrealized gain on available-for-sale securities, net	3,000	0	0
COMPREHENSIVE LOSS	$ (43,760,366)	$ (21,362,524)	$ (17,535,587)
BASIC AND DILUTED LOSS PER COMMON SHARE (in dollars per share)	$ (0.81)	$ (0.44)	$ (0.35)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING: BASIC AND DILUTED (in shares)	54,226,219	49,213,687	47,053,518

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (USD $)	Common Shares [Member]	Treasury Shares [Member]	Contributed Capital [Member]	Accumulated Deficit [Member]	Noncontrolling Interest [Member]	Accumulated Other Comprehensive Income [Member]	Total
BALANCE at Dec. 31, 2010	$ 101,135,428	$ 0	$ 93,972	$ (63,954,509)	$ 11,253,428	$ 897,338	$ 49,425,657
BALANCE (in shares) at Dec. 31, 2010	47,777,701	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common shares issued as part of acquisition of CTI assets	2,300,000						2,300,000
Common shares issued as part of acquisition of CTI assets (in shares)	261,959
Common shares issued as part of merger	2,600,000						2,600,000
Common shares issued as part of merger (in shares)	332,903
Treasury shares issued as part of investment in subsidiary	6,000,000	(6,000,000)					0
Treasury shares issued as part of investment in subsidiary (in shares)	1,286,174	(1,286,174)
Common shares retired as payment for exercise of options	(28,067)						(28,067)
Common shares retired as payment for exercise of options (in shares)	(6,435)
Common shares issued for rent							0
Common shares issued for consulting services							0
Exercise of options	251,981						251,981
Exercise of options (in shares)	450,660
Warrants exercised	425,000						425,000
Warrants exercised (in shares)	219,000
Warrants issued as part of merger with Glycosan	954,879						954,879
Outside investment in subsidiaries					3,213,500		3,213,500
Stock options granted for compensation	1,505,566						1,505,566
Stock options granted for compensation in subsidiary					273,635		273,635
Foreign currency translation gain (loss)						(1,020,087)	(1,020,087)
NET LOSS				(16,515,500)	(1,928,383)		(18,443,883)
BALANCE at Dec. 31, 2011	115,144,787	(6,000,000)	93,972	(80,470,009)	12,812,180	(122,749)	41,458,181
BALANCE (in shares) at Dec. 31, 2011	50,321,962	(1,286,174)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common shares issued as part of merger	1,802,684						1,802,684
Common shares issued as part of merger (in shares)	448,429
Sale of common shares, net of fees paid and amortized and syndication costs	1,002,220						1,002,220
Sale of common shares, net of fees paid and amortized and syndication costs (in shares)	314,386
Common shares issued for rent							0
Common shares issued for consulting services							0
Exercise of options	286,552						286,552
Exercise of options (in shares)	98,541						98,541
Subsidiary shares issued as part of merger with XenneX					2,501,415		2,501,415
Stock options granted for compensation	1,560,469						1,560,469
Stock options granted for compensation in subsidiary	24,531				274,656		299,187
Outside investment in subsidiary with BioTime common shares		(2,750,003)			2,750,003		0
Outside investment in subsidiary with BioTime common shares (in shares)		(592,533)
Sales of treasury shares		374,606					374,606
Sales of treasury shares (in shares)		78,598
Outside investment in subsidiaries in cash					250,000		250,000
Outside investment in subsidiaries with stock					1,740		1,740
Foreign currency translation gain (loss)						63,179	63,179
NET LOSS				(21,425,703)	(3,880,157)		(25,305,860)
BALANCE at Dec. 31, 2012	119,821,243	(8,375,397)	93,972	(101,895,712)	14,709,837	(59,570)	24,294,373
BALANCE (in shares) at Dec. 31, 2012	51,183,318	(1,800,109)					49,383,209
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common shares issued as part of investment in subsidiary	38,485,162	(38,485,162)
Common shares issued as part of investment in subsidiary (in shares)	9,808,812	(9,808,812)
8,000,000 Warrants issued as part of investment in subsidiary	18,276,406						18,276,406
Sale of common shares, net of fees paid and amortized and syndication costs	22,297,209						22,297,209
Sale of common shares, net of fees paid and amortized and syndication costs (in shares)	6,284,456
Warrants issued to outside investors	1,848,730						1,848,730
Common shares issued for rent	253,758						253,758
Common shares issued for rent (in shares)	73,553
Common shares issued for consulting services	173,100						173,100
Common shares issued for consulting services (in shares)	42,000
Exercise of options	46,000						46,000
Exercise of options (in shares)	20,000
Stock options granted for compensation	2,143,596						2,143,596
Stock options granted for compensation in subsidiary	111,197				789,981		901,178
Sales of treasury shares		3,826,602					3,826,602
Sales of treasury shares (in shares)		911,206
Outside investment in subsidiaries in cash					5,255,502		5,255,502
Outside investment in subsidiary with assets					15,732,524		15,732,524
Foreign currency translation gain (loss)						119,469	119,469
Unrealized gain on available-for-sale securities						3,000	3,000
NET LOSS				(43,882,835)	(9,026,291)		(52,909,126)
BALANCE at Dec. 31, 2013	$ 203,456,401	$ (43,033,957)	$ 93,972	$ (145,778,547)	$ 27,461,553	$ 62,899	$ 42,262,321
BALANCE (in shares) at Dec. 31, 2013	67,412,139	(10,697,715)					56,714,424

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss attributable to BioTime, Inc.	$ (43,882,835)	$ (21,425,703)	$ (16,515,500)
Net loss allocation to noncontrolling interest	(9,026,291)	(3,880,157)	(1,928,383)
Adjustments to reconcile net loss attributable to BioTime, Inc. to net cash used in operating activities:
Acquired in-process research and development	17,458,766	0	0
Depreciation expense	656,759	386,457	373,349
Amortization of intangible assets	3,295,716	2,446,975	1,991,200
Amortization of deferred consulting fees	65,118	598,465	598,465
Amortization of deferred license fees	109,500	109,500	109,500
Amortization of deferred rent	(12,766)	1,890	71,118
Amortization of deferred license, royalty and subscription revenues	(915,028)	(211,065)	(234,781)
Amortization of deferred grant revenues	0	(261,777)	0
Amortization of stock-based prepaid rent	84,586	0	0
Stock-based compensation	3,217,875	1,843,962	1,802,413
Reduction in receivables from the reversal of revenues	0	207,425	0
Write-off of security deposit	0	0	2,443
Write-off of expired inventory	0	0	1,510
(Gain)/Loss on sale or write-off of equipment	(5,120)	19,681	6,416
Bad debt expense	0	16,816	100,230
Deferred income tax benefit	(3,280,695)	0	0
Changes in operating assets and liabilities: [Abstract]
Accounts receivable, net	(180,933)	36,322	(120,678)
Grant receivable	560,286	(416,787)	261,777
Inventory	(123,378)	(4,141)	31,094
Prepaid expenses and other current assets	428,453	(228,370)	(704,854)
Other long term assets	(15,000)	0	0
Accounts payable and accrued liabilities	2,133,442	894,975	600,398
Other long term liabilities	(57,824)	(26,088)	(39,633)
Deferred revenues	(19,244)	212,102	0
Net cash used in operating activities	(29,508,613)	(19,679,518)	(13,593,916)
CASH FLOWS FROM INVESTING ACTIVITIES:
Payments of license fees	0	0	(1,500)
Purchase of equipment	(2,277,168)	(400,810)	(960,281)
Cash acquired in connection with merger with XenneX	0	292,387	0
Cash paid, net of cash acquired for CTI assets	0	0	(246,850)
Cash acquired in connection with merger with Glycosan	0	0	5,908
Payment of transaction fees to Geron	(978,104)	0	0
Payment of syndication fees incurred	(376,250)	0	0
Cash proceeds from sale of equipment	30,900	4,500	0
Security deposit received/(paid)	(64,965)	(764)	10
Net cash provided by/(used in) investing activities	(3,665,587)	(104,687)	(1,202,713)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercises of stock options	46,000	286,552	223,914
Proceeds from exercises of warrants	0	0	425,000
Proceeds from issuance of common shares	25,938,558	1,131,279	0
Fees paid on sale of common shares	(818,201)	(37,279)	0
Proceeds from sale of treasury shares	3,841,749	282,826	0
Proceeds from sale of common shares of subsidiary	5,255,502	250,000	3,213,500
Net cash used in financing activities	34,263,608	1,913,378	3,862,414
Effect of exchange rate changes on cash and cash equivalents	56,103	8,897	(178,812)
NET CHANGE IN CASH AND CASH EQUIVALENTS	1,145,511	(17,861,930)	(11,113,027)
CASH AND CASH EQUIVALENTS:
At beginning of year	4,349,967	22,211,897	33,324,924
At end of year	5,495,478	4,349,967	22,211,897
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during year for interest	3,090	315	326
SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES :
Common shares issued to Cell Cure in exchange for Cell Cure shares	3,499,999	0	0
Common shares issued for consulting services	173,100	0	0
Common shares issued for rent	253,758	0	0
Intangible assets acquired from Geron	29,017,009	0	0
Common shares issued to Asterias upon consummation of asset contribution (Treasury shares)	34,985,163	0	0
Common shares acquired in connection with investment in LifeMap as part of Share Exchange and Contribution Agreement	0	2,750,003	0
Common shares issued as part of merger with XenneX	0	1,802,684	0
Common shares issued in connection with investment in OncoCyte (Treasury shares)	0	0	6,000,000
Common shares issued in connection with the purchase of assets from CTI	0	0	2,300,000
Common shares issued as part of merger with Glycosan	0	0	2,600,000
Warrants issued to Asterias upon consummation of asset contribution	18,276,406	0	0
Warrants issued as part of merger with Glycosan	$ 0	$ 0	$ 954,879

Organization and Basis of Presentation

12 Months Ended

Dec. 31, 2013

Organization and Basis of Presentation

1. Organization and Basis of Presentation

General – BioTime is a biotechnology company engaged in two areas of biomedical research and product development. BioTime's primary focus is in the field of regenerative medicine; specifically human embryonic stem (“hES”) cell and induced pluripotent stem (“iPS”) cell technology. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products. BioTime and its subsidiaries plan to develop stem cell products for research and therapeutic use. Asterias Biotherapeutics, Inc. (“Asterias,” formerly known as BioTime Acquisition Corporation) entered into an Asset Contribution Agreement with BioTime and Geron Corporation (“Geron”) to acquire certain assets from Geron Corporation that had been used in Geron’s hES cell research and development programs, and Asterias is now using the acquired assets for the development of products for human therapeutic use in one or more of the following fields: neurology, oncology, orthopedics, and heart failure and myocardial infarction. OncoCyte Corporation (“OncoCyte”) is developing products and technologies to diagnose cancer. ES Cell International Pte Ltd. (“ESI”), a Singapore private limited company, developed hES cell lines and may market those cell lines and other BioTime research products in over-seas markets as part of BioTime’s ESI BIO division. OrthoCyte Corporation (“OrthoCyte”) is developing therapies to treat orthopedic disorders, diseases and injuries. ReCyte Therapeutics, Inc., formerly known as Embryome Sciences, Inc. (“ReCyte Therapeutics”), is developing therapies to treat a variety of cardiovascular and related ischemic disorders, as well as products for research using cell reprogramming technology. Cell Cure Neurosciences Ltd. (“Cell Cure Neurosciences”), is an Israel-based biotechnology company focused on developing stem cell-based therapies for retinal and neurological disorders, including the development of retinal pigment epithelial cells for the treatment of macular degeneration, and treatments for multiple sclerosis. LifeMap Sciences, Inc. (“LifeMap Sciences”) markets, sells and distributes GeneCards^®, the leading human gene database, and is developing an integrated database suite to complement GeneCards^® that will also include the LifeMap Discovery^® database of embryonic development, stem cell research and regenerative medicine, and MalaCards, the human disease database.

BioTime is focusing a portion of its efforts in the field of regenerative medicine on the development and sale of advanced human stem cell products and technology that can be used by researchers at universities and other institutions, at companies in the bioscience and biopharmaceutical industries, and at other companies that provide research products to companies in those industries. Products for the research market generally can be sold without regulatory (FDA) approval, and are therefore relatively near-term business opportunities when compared to therapeutic products.

BioTime previously developed blood plasma volume expanders and related technology for use in surgery, emergency trauma treatment and other applications. BioTime’s operating revenues are now derived primarily from licensing fees and advertising from the marketing of the LifeMap Sciences database products, from royalties and licensing fees related to the sale of its plasma volume expander product, Hextend^®, and from the sale of products for research.

The consolidated balance sheets as of December 31, 2013 and 2012, the consolidated statements of operations for the years ended December 31, 2013, 2012, and 2011, the consolidated statements of changes in equity for the years ended December 31, 2013, 2012, and 2011, and the consolidated statements of cash flows for the years ended December 31, 2013, 2012, and 2011 have been prepared by BioTime’s management in accordance with instructions from Form 10-K.

Principles of consolidation – BioTime’s consolidated financial statements include the accounts of its subsidiaries. The following table reflects BioTime’s ownership, directly or through one or more subsidiaries, of the outstanding shares of its subsidiaries.

Subsidiary	BioTime Ownership	Country
Asterias Biotherapeutics, Inc.	71.6%⁽¹⁾	USA
ReCyte Therapeutics, Inc.	94.8%	USA
OncoCyte Corporation	75.3%	USA
OrthoCyte Corporation	100%	USA
ES Cell International Pte Ltd.	100%	Singapore
BioTime Asia, Limited	81%	Hong Kong
Cell Cure Neurosciences Ltd.	62.5%	Israel
LifeMap Sciences, Inc.	73.2%	USA
LifeMap Sciences, Ltd.	(2)	Israel

(1)

BioTime’s percentage ownership was reduced from approximately 96.7% to approximately 71.6% on October 1, 2013 when Asterias issued common stock to BioTime and Geron Corporation pursuant to an Asset Contribution Agreement and sold common stock and warrants to a private investor for cash in a related transaction. See Note 15.

(2)	LifeMap Sciences, Ltd. is a wholly-owned subsidiary of LifeMap Sciences, Inc.

All material intercompany accounts and transactions have been eliminated in consolidation. The consolidated financial statements are presented in accordance with accounting principles generally accepted in the U.S. (“GAAP”) and with the accounting and reporting requirements of Regulation S-X of the Securities and Exchange Commission ("SEC"). As of December 31, 2013, BioTime consolidated Asterias, ReCyte Therapeutics, OncoCyte, OrthoCyte, ESI, Cell Cure Neurosciences, BioTime Asia, Limited (“BioTime Asia”), LifeMap Sciences, and LifeMap Sciences, Ltd. as BioTime has the ability to control their operating and financial decisions and policies through its ownership, and the noncontrolling interest is reflected as a separate element of equity on BioTime’s consolidated balance sheets.

Certain significant risks and uncertainties -The operations of BioTime and its subsidiaries are subject to a number of factors that can affect their operating results and financial condition. Such factors include but are not limited to, the following: the results of clinical trials of their respective therapeutic product and medical device candidates; their ability to obtain FDA and foreign regulatory approval to market their respective therapeutic and medical device product candidates; their ability to develop new stem cell research products and technologies; competition from products manufactured and sold or being developed by other companies; the price and demand for their products; their ability to obtain additional financing and the terms of any such financing that may be obtained; their ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products; the availability of ingredients used in their products; and the availability of reimbursement for the cost of their therapeutic products and medical devices (and related treatment) from government health administration authorities, private health coverage insurers, and other organizations.

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 46R

-Paragraph 4, 14, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number FAS140-4/FIN46(R)-8

-Paragraph 8, C1, C7

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 720

-SubTopic 15

-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=7880789&loc=SL6228881-111685

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 2-6

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 852

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 94-6

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Summary of Significant Accounting Policies	12 Months Ended
Summary of Significant Accounting Policies	Dec. 31, 2013
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Use of estimates – The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Revenue recognition – BioTime complies with SEC Staff Accounting Bulletin guidance on revenue recognition. Royalty revenues consist of product royalty payments. License fee revenues consist of fees under license agreements and are recognized when earned and reasonably estimable and also include subscription and advertising revenue from our online databases based upon respective subscription or advertising periods. BioTime recognizes revenue in the quarter in which the royalty reports are received, rather than the quarter in which the sales took place. When BioTime is entitled to receive up-front nonrefundable licensing or similar fees pursuant to agreements under which BioTime has no continuing performance obligations, the fees are recognized as revenues when collection is reasonably assured. When BioTime receives up-front nonrefundable licensing or similar fees pursuant to agreements under which BioTime does have continuing performance obligations, the fees are deferred and amortized ratably over the performance period. If the performance period cannot be reasonably estimated, BioTime amortizes nonrefundable fees over the life of the contract until such time that the performance period can be more reasonably estimated. Milestone payments, if any, related to scientific or technical achievements are recognized in income when the milestone is accomplished if (a) substantive effort was required to achieve the milestone, (b) the amount of the milestone payment appears reasonably commensurate with the effort expended, and (c) collection of the payment is reasonably assured. Grant income and the sale of research products are recognized as revenue when earned. Revenues from the sale of research products are primarily derived from the sale of hydrogels and stem cell products. Cash and cash equivalents – BioTime considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Accounts receivable and allowance for doubtful accounts - Trade accounts receivable and grants receivable are presented in the prepaid expenses and other current assets line item of the consolidated balance sheet. Total trade receivables amounted to approximately $575,900 and $395,000 and grants receivable amounted to approximately $539,300 and $1,059,000 as of December 31, 2013 and 2012, respectively. Some of these amounts are deemed uncollectible; as such BioTime recognized allowance for doubtful accounts in the amount of $116,816 as of December 31, 2013 and 2012. BioTime evaluates the collectability of its receivables based on a variety of factors, including the length of time receivables are past due and significant one-time events and historical experience. An additional reserve for individual accounts will be recorded if BioTime becomes aware of a customer’s inability to meet its financial obligations, such as in the case of bankruptcy filings or deterioration in the customer’s operating results or financial position. If circumstances related to customers change, estimates of the recoverability of receivables would be further adjusted. Concentrations of credit risk – Financial instruments that potentially subject BioTime to significant concentrations of credit risk consist primarily of cash and cash equivalents. BioTime limits the amount of credit exposure of cash balances by maintaining its accounts in high credit quality financial institutions. Cash equivalent deposits with financial institutions may occasionally exceed the limits of insurance on bank deposits; however, BioTime has not experienced any losses on such accounts. Inventory – Inventories are stated at the lower of cost or market. Cost, which includes amounts related to materials, labor, and overhead, is determined in a manner which approximates the first-in, first-out (“FIFO”) method. Equipment – Equipment is stated at cost. Equipment is being depreciated using the straight-line method over a period of 36 to 120 months. See Note 4. Intangible assets – Intangible assets with finite useful lives are amortized over estimated useful lives and intangible assets with indefinite lives are not amortized but rather are tested at least annually for impairment. Acquired in-process research and development intangible assets are accounted for depending on whether they were acquired as part of an acquisition of a business, or assets that do not constitute a business. When acquired in conjunction with acquisition of a business, these assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts and are capitalized as an asset. If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. However, when acquired in conjunction with an acquisition of assets that do not constitute a business (such as the acquisition of assets from Geron), in accordance with the accounting rules in ASC 805-50, such intangible assets related to in-process research and development (“IPR&D”) are expensed upon acquisition. Treasury stock – BioTime accounts for BioTime common shares issued to subsidiaries for future potential working capital needs as treasury stock on the consolidated balance sheet. BioTime has the intent and ability to register any unregistered shares to support the marketability of the shares. Warrants to purchase common stock – BioTime generally accounts for warrants issued in connection with equity financings as a component of equity. None of the warrants issued by BioTime as of December 31, 2013 include a conditional obligation to issue a variable number of shares; nor was there a deemed possibility that BioTime may need to settle the warrants in cash. If BioTime were to issue warrants with a conditional obligation to issue a variable number of shares or with the deemed possibility of a cash settlement, BioTime would record the fair value of the warrants as a liability at each balance sheet date and record changes in fair value in other income and expense in the consolidated statements of operations. Cost of sales – BioTime accounts for the cost of research products acquired for sale and any royalties paid as a result of any revenues in accordance with the terms of the respective licensing agreements as cost of sales on the consolidated statement of operations. Patent costs – Costs associated with obtaining patents on products or technology developed are expensed as general and administrative expenses when incurred. This accounting is in compliance with guidance promulgated by the Financial Accounting Standards Board (the “FASB”) regarding goodwill and other intangible assets. Reclassification – Certain prior year amounts have been reclassified to conform to the current year presentation. Research and development – BioTime complies with FASB requirements governing accounting for research and development costs. Research and development costs are expensed when incurred, and consist principally of salaries, payroll taxes, consulting fees, research and laboratory fees, and license fees paid to acquire patents or licenses to use patents and other technology from third parties. Foreign currency translation gain/(loss) and comprehensive loss – In countries in which BioTime operates, and the functional currency is other than the U.S. dollar, assets and liabilities are translated using published exchange rates in effect at the consolidated balance sheet date. Revenues and expenses and cash flows are translated using an approximate weighted average exchange rate for the period. Resulting translation adjustments are recorded as a component of accumulated other comprehensive income on the consolidated balance sheet. For the fiscal years ended December 31, 2013 and 2012, comprehensive loss includes gain of $122,469 and $63,179, respectively which is largely from foreign currency translation. For the fiscal year ended December 31, 2013 and 2012, foreign currency transaction loss amounted to $133,479 and $34,233, respectively. Income taxes – BioTime accounts for income taxes in accordance with GAAP requirements, which prescribe the use of the asset and liability method, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and rates in effect. Valuation allowances are established when necessary to reduce deferred tax assets when it is more likely than not that a portion or all of the deferred tax assets will not be realized. The FASB guidance also prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not sustainable upon examination by taxing authorities. For 2013, Asterias will file a separate U.S. federal and state income tax returns but effectively BioTime will combine Asterias' tax provision with BioTime's. BioTime recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties as of December 31, 2013 and 2012. BioTime files its income tax returns in the U.S. federal and various state and local and foreign jurisdictions. Generally, BioTime is no longer subject to income tax examinations by major taxing authorities for years before 2010. Any potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with U.S. federal, state and local and foreign tax laws. Management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months Stock-based compensation – BioTime adopted accounting standards governing share-based payments, which require the measurement and recognition of compensation expense for all share-based payment awards made to directors and employees, including employee stock options, based on estimated fair values. In March 2005, the SEC issued additional guidelines which provide supplemental implementation guidance for valuation of share-based payments. BioTime has applied the provisions of this guidance in such valuations as well. Consistent with those guidelines, BioTime utilizes the Black-Scholes Merton option pricing model. BioTime's determination of fair value of share-based payment awards on the date of grant using that option-pricing model is affected by BioTime's stock price as well as by assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, BioTime's expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. The expected term of options granted is derived from historical data on employee exercises and post-vesting employment termination behavior. The risk-free rate is based on the U.S. Treasury rates in effect during the corresponding period of grant. Although the fair value of employee stock options is determined in accordance with recent FASB guidance, changes in the subjective assumptions can materially affect the estimated value. Impairment of long-lived assets – BioTime’s long-lived assets, including intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. If an impairment indicator is present, BioTime will evaluate recoverability by a comparison of the carrying amount of the assets to future undiscounted net cash flows expected to be generated by the assets. If the assets are impaired, the impairment will be recognized and is measured by the amount by which the carrying amount exceeds the estimated fair value of the assets. Deferred license and consulting fees – Deferred license and consulting fees consist of the value of warrants issued to third parties for services, and deferred license fees paid to acquire rights to use the proprietary technologies of third parties. The value of the warrants is being amortized over the period the services are being provided, and the license fees are being amortized over the estimated useful lives of the licensed technologies or licensed research products. See Note 6. Loss per share – Basic net loss per share is computed by dividing net loss attributable to BioTime by the weighted-average number of common shares outstanding for the period. Diluted net loss per share reflects the weighted-average number of common shares outstanding plus the potential effect of dilutive securities or contracts which are convertible to common shares, such as options and warrants (using the treasury stock method) and shares issuable in future periods, except in cases where the effect would be anti-dilutive. Diluted loss per share for years ended December 31, 2013, 2012, and 2011 excludes any effect from 10,697,715 treasury shares, 4,567,135 options and 9,751,615 warrants, 1,800,109 treasury shares, 3,681,301 options and 556,613 warrants, and 1,286,174 treasury shares, 3,408,905 options and 636,613 warrants, respectively. Fair value of financial instruments – The fair value of BioTime’s assets and liabilities, which qualify as financial instruments under FASB guidance regarding disclosures about fair value of financial instruments, approximate the carrying amounts presented in the accompanying consolidated balance sheets. Effect of recently issued and recently adopted accounting pronouncements – There are no recently issued accounting standards which are not yet effective which BioTime believes would materially impact the consolidated financial statements.

The entire disclosure for all significant accounting policies of the reporting entity.

+ References+ Details

Inventory	12 Months Ended
Inventory	Dec. 31, 2013
Inventory [Abstract]
Inventory	3. Inventory At December 31, 2013, BioTime, held $165,771 of inventory of finished products on-site at its corporate headquarters in Alameda, California. At that same date $12,923 of inventory of finished products was held by a third party on consignment. At December 31, 2012, BioTime, held $41,494 of inventory of finished products on-site at its corporate headquarters in Alameda, California. At that same date $13,822 of inventory of finished products was held by a third party on consignment.

The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.

+ References+ Details

Equipment

12 Months Ended

Dec. 31, 2013

Equipment [Abstract]

Equipment

4. Equipment

At December 31, 2013 and December 31, 2012, equipment, furniture and fixtures were comprised of the following:

	2013			2012
Equipment, furniture and fixtures	$	4,431,586		$	2,098,812
Accumulated depreciation		(1,433,853	)		(750,258	)
Equipment net of accumulated depreciation	$	2,997,733		$	1,348,554

Depreciation expense amounted to $656,759 and $386,457 for the years ended December 31, 2013 and 2012, respectively. The difference between the depreciation expense recognized in the consolidated statement of operations and the increase in accumulated depreciation of $683,595 per the consolidated balance sheet is partially attributed to a write off of $1,500 of fully depreciated assets offset by foreign currency rates.

The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.

+ References+ Details

Intangible assets

12 Months Ended

Dec. 31, 2013

Intangible assets [Abstract]

Intangible assets

5. Intangible assets

At December 31, 2013 and December 31, 2012, intangible assets and accumulated intangible assets were comprised of the following:

	2013			2012
Intangible assets	$	54,719,918		$	25,702,909
Accumulated amortization		(8,511,833	)		(5,216,117	)
Intangible assets, net	$	46,208,085		$	20,486,792

BioTime amortizes its intangible assets over an estimated period of 10 years on a straight line basis. BioTime recognized $3,295,716 in amortization expense of intangible assets during the year ended December 31, 2013. Amortization expense for the year ended December 31, 2012 amounted to $2,446,975. See Notes 11, 12, 13, 14, and 15.

Amortization of intangible assets for periods subsequent to December 31, 2013 is as follows:

Year Ended	Amortization
December 31,	Expense
2014	$	5,472,123
2015		5,472,123
2016		5,472,123
2017		5,472,123
Thereafter		24,319,593
Total	$	46,208,085

Royalty Obligation and Deferred License Fees [Abstract]

The entire disclosure for all or part of the information related to intangible assets.

+ References+ Details

Royalty Obligation and Deferred License Fees

12 Months Ended

Dec. 31, 2013

Royalty Obligation and Deferred License Fees

6. Royalty Obligation and Deferred License Fees

BioTime amortizes deferred license fees over the estimated useful lives of the licensed technologies or licensed research products. BioTime is applying a 10 year estimated useful life to the technologies and products that it is currently licensing. The estimation of the useful life any technology or product involves a significant degree of inherent uncertainty, since the outcome of research and development or the commercial life a new product cannot be known with certainty at the time that the right to use the technology or product is acquired. BioTime will review its amortization schedules for impairments that might occur earlier than the original expected useful lives.

WARF License—Research Products

On January 3, 2008, BioTime entered into a Commercial License and Option Agreement with Wisconsin Alumni Research Foundation (“WARF”). The WARF license permits BioTime to use certain patented and patent pending technology belonging to WARF, as well as certain stem cell materials, for research and development purposes, and for the production and marketing of products used as research tools, including in drug discovery and development. BioTime or ReCyte Therapeutics will pay WARF royalties on the sale of products and services using the technology or stem cells licensed from WARF. The royalty will range from 2% to 4%, depending on the kind of products sold. The royalty rate is subject to certain reductions if BioTime also becomes obligated to pay royalties to a third party in order to sell a product. In March 2009, BioTime amended its license agreement with WARF. The amendment increased the license fee from the original $225,000 to $295,000, of which $225,000 was paid in cash and $70,000 was paid by delivering BioTime common shares having a market value of $70,000 as of March 2, 2009. The amendment extended until March 2, 2010 the dates for payment of the $215,000 balance of the cash license fee and $20,000 in remaining reimbursement of costs associated with preparing, filing, and maintaining the licensed patents. The commencement date for payment of an annual $25,000 license maintenance fee was also extended to March 2, 2010. The licensing fees less the amortized portion were included in deferred license fees in BioTime’s consolidated balance sheet as of December 31, 2013 and 2012.

ReCyte Therapeutics Licenses from ACT

On July 10, 2008, ReCyte Therapeutics entered into a License Agreement with Advanced Cell Technology, Inc. (“ACT”), under which ReCyte Therapeutics acquired exclusive worldwide rights to use ACT’s technology for methods to accelerate the isolation of novel cell strains from pluripotent stem cells. ReCyte subsequently assigned the license to BioTime. ReCyte Therapeutics paid ACT a $250,000 license fee and will pay an 8% royalty on sales of products, services, and processes that utilize the licensed technology. Once a total of $1,000,000 of royalties has been paid, no further royalties will be due. The license will expire in twenty years or upon the expiration of the last to expire of the licensed patents, whichever is later. The $250,000 license fee less the amortized portion is included in deferred license fees in BioTime’s consolidated balance sheet as of December 31, 2013 and 2012.

On August 15, 2008, ReCyte Therapeutics entered into a License Agreement and a Sublicense Agreement with ACT under which ReCyte Therapeutics acquired world-wide rights to use an array of ACT technology (the “ACT License”) and technology licensed by ACT from affiliates of Kirin Pharma Company, Limited (the “Kirin Sublicense”). The ACT License and Kirin Sublicense permit the commercialization of products in human therapeutic and diagnostic product markets.

The technology licensed by ReCyte Therapeutics covers methods to transform cells of the human body, such as skin cells, into an embryonic state in which the cells will be pluripotent. Under the ACT License, ReCyte Therapeutics paid ACT a $200,000 license fee and will pay a 5% royalty on sales of products, services, and processes that utilize the licensed ACT technology, and 20% of any fees or other payments (other than equity investments, research and development costs, loans and royalties) received by ReCyte Therapeutics from sublicensing the ACT technology to third parties. Once a total of $600,000 of royalties has been paid, no further royalties will be due. The license will expire in twenty years or upon the expiration of the last-to-expire of the licensed patents, whichever is later. The $200,000 license fee payment less the amortized portion is included in deferred license fees in BioTime’s consolidated balance sheet as of December 31, 2013 and 2012.

Under the Kirin Sublicense, ReCyte Therapeutics has paid ACT a $50,000 license fee and will pay a 3.5% royalty on sales of products, services, and processes that utilize the licensed ACT technology, and 20% of any fees or other payments (other than equity investments, research and development costs, loans and royalties) received by ReCyte Therapeutics from sublicensing the Kirin Technology to third parties. ReCyte Therapeutics will also pay to ACT or to an affiliate of Kirin Pharma Company, Limited (“Kirin”), annually, the amount, if any, by which royalties payable by ACT under its license agreement with Kirin are less than the $50,000 annual minimum royalty due. Those payments by ReCyte Therapeutics will be credited against other royalties payable to ACT under the Kirin Sublicense. The license will expire upon the expiration of the last to expire of the licensed patents, or May 9, 2016 if no patents are issued. The $50,000 license fee payment less the amortized portion is included in deferred license fees in BioTime’s consolidated balance sheet as of December 31, 2013 and 2012.

ReCyte Therapeutics License from RGI

On February 29, 2009, ReCyte Therapeutics entered into a Stem Cell Agreement with Reproductive Genetics Institute (“RGI”). In partial consideration of the rights and licenses granted to ReCyte Therapeutics by RGI, BioTime issued to RGI 32,259 common shares, having a market value of $50,000 on the effective date of the Stem Cell Agreement. This $50,000 payment less the amortized portion is included in deferred license fees in BioTime’s consolidated balance sheet as of December 31, 2013 and 2012.

OncoCyte License from SBMRI

Through BioTime’s acquisition of the assets of Cell Targeting, Inc. during March 2011, BioTime acquired a royalty-bearing, exclusive, worldwide license from the Sanford-Burnham Medical Research Institute (“SBMRI”) to use certain patents pertaining to homing peptides for preclinical research investigations of cell therapy treatments, and to enhance cell therapy products for the treatment and prevention of disease and injury in conjunction with BioTime’s own proprietary technology or that of a third party. BioTime assigned the SBMRI license to OncoCyte during July 2011. OncoCyte will pay SBMRI a royalty of 4% on the sale of pharmaceutical products, and 10% on the sale of any research-use products that OncoCyte develops using or incorporating the licensed technology; and 20% of any payments OncoCyte receives for sublicensing the patents to third parties. The royalties payable to SBMRI may be reduced by 50% if royalties or other fees must be paid to third parties in connection with the sale of any products. An annual license maintenance fee is payable each year during the term of the license, and after commercial sales of royalty bearing products commence, the annual fee will be credited towards OncoCyte's royalty payment obligations for the applicable year. OncoCyte will reimburse SBMRI for 25% of the costs incurred in filing, prosecuting, and maintaining patent protection, subject to OncoCyte’s approval of the costs. OncoCyte incurred no royalty expenses to date as of December 31, 2013. See Note 11.

Cell Cure Neurosciences License from Hadasit

Cell Cure Neurosciences has entered into an Amended and Restated Research and License Agreement with Hadasit Medical Research Services and Development, Ltd. (“Hadasit”) under which Cell Cure Neurosciences received an exclusive license to use certain of Hadasit’s patented technologies for the development and commercialization for hES cell-derived cell replacement therapies for retinal degenerative diseases. Cell Cure Neurosciences paid Hadasit 249,058 New Israeli Shekels as a reimbursement for patent expenses incurred by Hadasit, and pays Hadasit quarterly fees for research and product development services under a related Product Development Agreement.

If Teva Pharmaceutical Industries Ltd. (“Teva”) exercises its option to license OpRegen^® or OpRegen^®-Plus under the terms of a Research and Exclusive License Option Agreement (the “Teva License Option Agreement”), Cell Cure Neurosciences will pay Hadasit 30% of all payments made by Teva to Cell Cure Neurosciences, other than payments for research, reimbursements of patent expenses, loans or equity investments.

If Teva does not exercise its option and Cell Cure Neurosciences instead commercializes OpRegen^® or OpRegen^®-Plus itself or sublicenses the Hadasit patents to a third party for the completion of development or commercialization of OpRegen^® or OpRegen^®-Plus, Cell Cure Neurosciences will pay Hadasit a 5% royalty on sales of products that utilize the licensed technology. Cell Cure Neurosciences will also pay sublicensing fees ranging from 10% to 30% of any payments Cell Cure Neurosciences receives from sublicensing the Hadasit patents to companies other than Teva. Commencing in January 2017, Hadasit will be entitled to receive an annual minimum royalty payment of $100,000 that will be credited toward the payment of royalties and sublicense fees otherwise payable to Hadasit during the calendar year. If Cell Cure Neurosciences or a sublicensee other than Teva paid royalties during the previous year, Cell Cure Neurosciences may defer making the minimum royalty payment until December and will be obligated to make the minimum annual payment to the extent that royalties and sublicensing fee payments made during that year are less than $100,000.

If Teva does not exercise its option under the Teva License Option Agreement and instead Cell Cure Neurosciences or a sublicensee other than Teva conducts clinical trials of OpRegen^® or OpRegen^®-Plus, Hadasit will be entitled to receive certain payments from Cell Cure Neurosciences upon the first attainment of certain clinical trial milestones in the process of seeking regulatory approval to market a product developed by Cell Cure Neurosciences using the licensed patents. Hadasit will receive $250,000 upon the enrollment of patients in the first Phase I clinical trial, $250,000 upon the submission of Phase II clinical trial data to a regulatory agency as part of the approval process, and $1 million upon the enrollment of the first patient in the first Phase III clinical trial.

BioTime License for the University of Utah

Through the merger of Glycosan into OrthoCyte during March 2011, BioTime acquired a license from the University of Utah to use certain patents in the production and sale of certain hydrogel products. Under the License Agreement, the scope of which was expanded by an amendment during August 2012, BioTime will pay a 3% royalty on sales of products and services performed that utilize the licensed patents. Commencing in 2014, BioTime will be obligated to pay minimum royalties to the extent that actual royalties on products sales and services utilizing the patents are less than the minimum royalty amount. The minimum royalty amounts are $2,500 in 2014 and $30,000 each year thereafter during the term of the License Agreement. BioTime shall also pay the University of Utah 30% of any sublicense fees or royalties received under any sublicense of the licensed patents. See Note 12.

BioTime will pay the University of Utah $5,000 upon the issuance of each of the first five licensed patents issued in the U.S., subject to reduction to $2,500 for any patent that the University has licensed to two or more other licensees for different uses. BioTime will also pay a $225,000 milestone fee within six months after the first sale of a “tissue engineered product” that utilizes a licensed patent. A tissue engineered product is defined as living human tissues or cells on a polymer platform, created at a place other than the point-of-care facility, for transplantation into a human patient.

BioTime License from Cornell University

On August 23, 2011, BioTime entered into a License Agreement with Cornell University for the worldwide development and commercialization of technology for the differentiation of hES cells into vascular endothelial cells.

Cornell will be entitled to receive a nominal initial license fee and nominal annual license maintenance fees. The obligation to pay annual license maintenance fees will end when the first human therapeutic products developed under the license is sold. BioTime will pay Cornell a milestone payment upon the achievement of a research product sale milestone amount, and will make milestone payments upon the attainment of certain FDA approval milestones for therapeutic products developed under the license, including (i) the first Phase II clinical trial dosing of a human therapeutic product, (ii) the first Phase III clinical trial dosing of a human therapeutic product; (iii) FDA approval of the first human therapeutic product for age-related vascular disease; and (iv) FDA approval of the first human therapeutic product for cancer.

BioTime will pay Cornell royalties on the sale of products and services using the license, and will share with Cornell a portion of any cash payments, other than royalties, that BioTime receives for the grant of sublicenses to non-affiliates. The potential royalty percentage rates to be paid to Cornell will be in the low to mid-single digit range depending on the product. BioTime will also reimburse Cornell for costs related to the patent applications and any patents that may issue that are covered by the license.

In conjunction with the License Agreement, BioTime also entered into a Sponsored Research Agreement under which scientists at Weill Cornell Medical College will engage in certain research for BioTime over a three year period beginning August 2011.

Asterias License from WARF

Asterias has entered into a Non-Exclusive License Agreement with WARF under which Asterias was granted a worldwide non-exclusive license under certain WARF patents and WARF-owned embryonic stem cell lines to develop and commercialize therapeutic, diagnostic and research products. The licensed patents include patents covering primate embryonic stem cells as compositions of matter, as well as methods for growth and differentiation of primate embryonic stem cells. The licensed stem cell lines include the H1, H7, H9, H13 and H14 hES cell lines.

In consideration of the rights licensed, Asterias has agreed to pay WARF an upfront license fee, payments upon the attainment of specified clinical development milestones, royalties on sales of commercialized products, and, subject to certain exclusions, a percentage of any payments that Asterias may receive from any sublicenses that it may grant to use the licensed patents or stem cell lines.

The license agreement will terminate with respect to licensed patents upon the expiration of the last licensed patent to expire. Asterias may terminate the license agreement at any time by giving WARF prior written notice. WARF may terminate the license agreement if payments of earned royalties, once begun, cease for a specified period of time or if Asterias and any third parties collaborating or cooperating with Asterias in the development of products using the licensed patents or stem cell lines fail to spend a specified minimum amount on research and development of products relating to the licensed patents or stem cell lines for a specified period of time. WARF also has the right to terminate the license agreement if Asterias breaches the license agreement or becomes bankrupt or insolvent or if any of the licensed patents or stem cell lines are offered to creditors

Asterias License from the University of California

Geron assigned to Asterias its Exclusive License Agreement with The Regents of the University of California for patents covering a method for directing the differentiation of multipotential hES cells to glial-restricted progenitor cells that generate pure populations of oligodendrocytes for remyelination and treatment of spinal cord injury. Pursuant to this agreement, Asterias has an exclusive worldwide license under such patents, including the right to grant sublicenses, to create products for biological research, drug screening, and human therapy using the licensed patents. Under the license agreement, Asterias will be obligated to pay the university a royalty of 1% from sales of products that are covered by the licensed patent rights, and a minimum annual royalty of $5,000 starting in the year in which the first sale of a product covered by any licensed patent rights occurs, and continuing for the life of the applicable patent right under the agreement. The royalty payments due are subject to reduction, but not by more than 50%, to the extent of any payments that Asterias may be obligated to pay to a third party for the use of patents or other intellectual property licensed from the third party in order to make, have made, use, sell, or import products or otherwise exercise its rights under the Exclusive License Agreement. Asterias will be obligated to pay the university 7.5% of any proceeds, excluding debt financing and equity investments, and certain reimbursements, that its receives from sublicensees, other than Asterias’ affiliates and joint ventures relating to the development, manufacture, purchase, and sale of products, processes, and services covered by the licensed patent. The license agreement will terminate on the expiration of the last-to-expire of the university's issued licensed patents. If no further patents covered by the license agreement are issued, the license agreement would terminate in 2024. The university may terminate the agreement in the event of Asterias’ breach of the agreement. Asterias can terminate the agreement upon 60 days' notice.

Asterias Sublicenes from Geron

Asterias has received from Geron an exclusive sublicense under certain patents owned by the University of Colorado’s University License Equity Holdings, Inc. relating to telomerase (the “Telomerase Sublicense”). The Telomerase Sublicense entitles Asterias to use the technology covered by the patents in the development of VAC1 and VAC2 as immunological treatments for cancer. Under the Telomerase Sublicense, Asterias paid Geron a one-time upfront license fee of $65,000, and will pay Geron an annual license maintenance fee of $10,000 due on each anniversary of the effective date of the Telomerase Sublicense, and a 1% royalty on sales of any products that Asterias may develop and commercialize that are covered by the sublicensed patents. The Telomerase Sublicense will expire concurrently with the expiration of Geron’s license. That license will terminate during April 2017 when the licensed patents expire. The Telomerase Sublicense may also be terminated by Asterias by giving Geron 90 days written notice, by Asterias or by Geron if the other party breaches its obligations under the sublicense agreement and fails to cure their breach within the prescribed time period, or by Asterias or by Geron upon the filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings, or upon an assignment of a substantial portion of the assets for the benefit of creditors by the other party.

As of December 31, 2013, amortization of deferred license fees was as follows:

Year Ended	Deferred License
December 31,	Fees
2014	$	111,000
2015		111,000
2016		111,000
2017		111,000
Thereafter		111,833
Total	$	555,833

The current portion in the amount of $111,000 is included in prepaid expenses and other current assets. Noncurrent portion of $444,833 is included in deferred license and consulting fees.

The entire disclosure for deferred revenues at the end of the reporting period, and description and amounts of significant changes that occurred during the reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References+ Details

Related Party Transactions	12 Months Ended
Related Party Transactions	Dec. 31, 2013
Related Party Transactions [Abstract]
Related Party Transactions	8. Related Party Transactions BioTime currently pays $5,050 per month for the use of approximately 900 square feet of office space in New York City, which is made available to BioTime on a month-by-month basis by one of its directors at his cost for use in conducting meetings and other business affairs. On January 29, 2013, in accordance with a November 1, 2012 Share Purchase Agreement between BioTime and Cell Cure Neurosciences, BioTime purchased 87,456 Cell Cure Neurosciences ordinary shares in exchange for 906,735 of BioTime common shares. On October 1, 2013, BioTime issued 8,902,077 common shares and warrants to purchase 8,000,000 common shares to Asterias pursuant to the Asset Contribution Agreement discussed in Note 15.

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph b

-Article 3A

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 57

-Paragraph 1-4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Equity

12 Months Ended

Dec. 31, 2013

Equity [Abstract]

Equity

9. Equity

BioTime has issued warrants to purchase its common shares. Activity related to warrants in 2013, 2012, and 2011 is presented in the table below:

	Number of Warrants			Per share exercise price		Weighted Average Exercise Price
Outstanding, January 1, 2011		649,000		$	0.68 - 10.00	$	6.42
Granted in 2011		206,613			10.00		10.00
Exercised in 2011		(219,000	)		0.68 - 3.00		1.94
Outstanding, December 31, 2011		636,613		$	3.00 – 10.00	$	9.13
Expired in 2012		(80,000	)		3.00		3.00
Outstanding, December 31, 2012		556,613		$	10.00	$	10.00
Granted in 2013		9,195,002			5.00		5.00
Outstanding, December 31, 2013		9,751,615		$	5.00 – 10.00	$	5.29

At December 31, 2013, 9,751,615 warrants to purchase common shares with a weighted average exercise price of $5.29 and a weighted average remaining contractual life of 0.32 years were outstanding.

At December 31, 2012, 556,613 warrants to purchase common shares with a weighted average exercise price of $10.00 and a weighted average remaining contractual life of 1.32 years were outstanding.

At December 31, 2011, 636,613 warrants to purchase common shares with a weighted average exercise price of $9.13 and a weighted average remaining contractual life of 1.68 years were outstanding.

A summary of all option activity under the subsidiary option plans (see Note 10) for the years ended December 31, 2013, 2012, and 2011 is as follows:

	Options Available for Grant			Number of Options Outstanding			Weighted Average Exercise Price
January 1, 2011		7,703,060			4,312,640		$	0.74
Added upon adoption of option plan in 2011		8,000,000			-			-
Granted in 2011		(4,685,000	)		4,685,000			0.36
Forfeited/Exercised in 2011		200,000			(200,000	)		0.05
December 31, 2011		11,218,060			8,797,640		$	0.56
Reverse stock split and change in plan in 2012		(3,697,014	)		(2,460,717	)		-
Granted in 2012		(1,479,490	)		1,479,490			1.39
Forfeited/Exercised in 2012		-			-			-
December 31, 2012		6,041,556			7,816,413		$	0.93
Increase option pool		500,000			-			-
Granted in 2013		(4,434,995	)		4,434,995			2.11
Expired/Forfeited/Exercised in 2013		785,000			(785,000	)		1.95
December 31, 2013		2,891,561			11,466,408		$	1.32

Preferred Shares

BioTime is authorized to issue 2,000,000 preferred shares. BioTime’s shareholders approved an increase in the number of authorized preferred shares from 1,000,000 to 2,000,000 in May 2013. The preferred shares may be issued in one or more series as the board of directors may by resolution determine. The board of directors is authorized to fix the number of shares of any series of preferred shares and to determine or alter the rights, references, privileges, and restrictions granted to or imposed on the preferred shares as a class, or upon any wholly unissued series of any preferred shares. The board of directors may, by resolution, increase or decrease (but not below the number of shares of such series then outstanding) the number of shares of any series of preferred shares subsequent to the issue of shares of that series.

As of December 31, 2013 and 2012, BioTime has no issued and outstanding preferred shares.

Common shares

BioTime is authorized to issue 125,000,000 common shares with no par value. BioTime’s shareholders approved an increase in the number of authorized common shares from 75,000,000 to 125,000,000 in May 2013. As of December 31, 2013, BioTime has 67,412,139 issued and 56,714,424 outstanding common shares. As of December 31, 2012, BioTime had 51,183,318 issued and 49,383,209 outstanding common shares. The difference of 10,697,715 and 1,800,109 common shares as of December 31, 2013 and 2012, respectively is attributed to treasury shares held by BioTime subsidiaries which are accounted for as treasury stock on the consolidated balance sheet.

Significant common share transactions during the year ended December 31, 2013 are as follows:

In January 2013, as additional consideration for the lease for an office and research facility located in Menlo Park, California, BioTime issued to the landlord 73,553 BioTime common shares having a market value of $242,726, determined based upon the average closing price of BioTime common shares on the NYSE MKT for a designated period of time prior to the signing of the lease. For accounting purposes, these shares were revalued at $253,758 which was based on the closing price of BioTime common shares on the NYSE MKT on the date the lease was fully executed at which time the shares were issued.

In January 2013, BioTime and a private investor entered into a Stock and Warrant Purchase Agreement under which BioTime received $5,000,000 for the sale of 1,350,000 BioTime common shares and warrants to purchase 649,999 additional BioTime common shares at an exercise price of $5.00 per share.

In January 2013, in accordance with a November 1, 2012 Share Purchase Agreement between BioTime and Cell Cure Neurosciences, BioTime purchased 87,456 Cell Cure Neurosciences ordinary shares in exchange for 906,735 of BioTime common shares.

In June 2013, BioTime sold an aggregate of 2,180,016 common shares and 545,004 warrants to purchase common shares, in "units" with each unit consisting of one common share and one-quarter of a warrant, at an offering price of $4.155 per unit, to certain investors through an offering registered under the Securities Act. BioTime received gross proceeds of $9,057,967 from the sale of the common shares and warrants. The warrants have an initial exercise price of $5.00 per share and are exercisable during the five year period beginning on the date of issuance, June 6, 2013.

In October 2013, BioTime issued 8,902,077 common shares and warrants to purchase 8,000,000 common shares to Asterias under the Asset Contribution Agreement.

During 2013 BioTime sold 3,665,646 BioTime common shares for gross proceeds of $15,722,339 at prevailing market prices through BioTime’s $25 million Controlled Equity Offering facility which was established with Cantor Fitzgerald & Co.

Significant common share transactions during the year ended December 31, 2012 are as follows:

BioTime received total cash of $286,552 for the exercise of 98,541 options at a weighted average exercise price of $2.91.

BioTime issued 448,429 common shares as consideration for the merger of XenneX, Inc. with LifeMap Sciences.

In July and in December 2012, LifeMap Sciences received $250,000 cash and 592,533 BioTime common shares having a market value of $2,750,003 from certain private investors in exchange for 1,714,287 LifeMap Sciences shares of common stock. LifeMap Sciences sold 78,598 BioTime common shares for gross proceeds of $282,826 during 2012 and the remaining 513,935 BioTime common shares held by LifeMap Sciences are accounted for as treasury stock as of December 31, 2012. See Note 8.

During 2012 BioTime sold 314,386 BioTime common shares for gross proceeds of $1,131,279 at prevailing market prices through BioTime’s Controlled Equity Offering facility with Cantor Fitzgerald & Co.

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section B

-Paragraph 7, 11A

-Chapter 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 20: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 21: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 22: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 23: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

+ Details

Stock Option Plans

12 Months Ended

Dec. 31, 2013

Stock Option Plans [Abstract]

Stock Option Plans

10. Stock Option Plans

During 2002, BioTime adopted the 2002 Employee Stock Option Plan (the “2002 Plan”), which was amended in 2004, 2007, and 2009 to reserve additional common shares for issuance under options or restricted stock awards granted to eligible persons. The 2002 Plan expired during September 2012 and no additional grants of options or awards of restricted stock may be made under the 2002 Plan.

During December 2012, BioTime’s Board of Directors approved the 2012 Equity Incentive Plan (the “2012 Plan”) under which BioTime has reserved 4,000,000 common shares for the grant of stock options or the sale of restricted stock. No options may be granted under the 2012 Plan more than ten years after the date upon which the 2012 Plan was adopted by the Board of Directors, and no options granted under the 2012 Plan may be exercised after the expiration of ten years from the date of grant. Under the 2012 Plan, options to purchase common shares may be granted to employees, directors and certain consultants at prices not less than the fair market value at date of grant, subject to certain limited exceptions for options granted in substitution of other options. Options may be fully exercisable immediately, or may be exercisable according to a schedule or conditions specified by the Board of Directors or the Compensation Committee. The 2012 Plan also permits BioTime to award restricted stock for services rendered or to sell common shares to employees subject to vesting provisions under restricted stock agreements that provide for forfeiture of unvested shares upon the occurrence of specified events under a restricted stock award agreement. BioTime may permit employees or consultants, but not officers or directors, who purchase stock under restricted stock purchase agreements, to pay for their shares by delivering a promissory note that is secured by a pledge of their shares.

BioTime may also grant stock appreciation rights (“SARs”) and hypothetical units issued with reference to BioTime common shares (“Restricted Stock Units”) under the Plan. An SAR is the right to receive, upon exercise, an amount payable in cash or shares or a combination of shares and cash, as determined by the Board of Directors or the Compensation Committee, equal to the number of shares subject to the SAR that is being exercised multiplied by the excess of (a) the fair market value of a BioTime common share on the date the SAR is exercised, over (b) the exercise price specified in the SAR Award agreement.

The terms and conditions of a grant of Restricted Stock Units will be determined by the Board of Directors or Compensation Committee. No shares of stock will be issued at the time a Restricted Stock Unit is granted, and BioTime will not be required to set aside a fund for the payment of any such award. A recipient of Restricted Stock Units will have no voting rights with respect to the Restricted Stock Units. Upon the expiration of the restrictions applicable to a Restricted Stock Unit, BioTime will either issue to the recipient, without charge, one common share per Restricted Stock Unit or cash in an amount equal to the fair market value of one common share.

On January 1, 2006, BioTime adopted a new accounting pronouncement, which requires the measurement and recognition for all share-based payment awards made to BioTime’s employees and directors, including employee stock options. The following table summarizes stock-based compensation expense related to employee and director stock options awards for the years ended December 31, 2013, 2012, and 2011, which was allocated as follows:

	Year Ended December 31,
All stock-based compensation expense:	2013		2012		2011
Research and Development	$	829,938	$	815,052	$	885,581
General and Administrative		2,214,836		1,028,910		916,832
All stock-based compensation expense included in expenses	$	3,044,774	$	1,843,962	$	1,802,413

As of December 31, 2013, total unrecognized compensation costs related to unvested stock options was $5,609,851, which is expected to be recognized as expense over a weighted average period of approximately 5.48 years.

For all applicable periods, the value of each employee or director stock option was estimated on the date of grant using the Black-Scholes Merton model for the purpose of the pro forma financial disclosures in accordance with a new accounting pronouncement.

The weighted-average estimated fair value of stock options granted during the years ended December 31, 2013 and 2012 was $4.13 per share in both years, using the Black-Scholes Merton model with the following weighted-average assumptions:

	Year Ended December 31,
	2013			2012

Expected life (in years)		6.68			6.35
Risk-free interest rates		1.51	%		1.06	%
Volatility		95.22	%		98.88	%
Dividend yield		0	%		0	%

General Option Information

A summary of all option activity under the 2002 Plan and the 2012 Plan for the years ended December 31, 2013, 2012, and 2011, is as follows:

	Options Available for Grant			Number of Options Outstanding			Weighted Average Exercise Price
January 31, 2011		1,842,168			3,320,590		$	1.13
Granted under 2002 Plan		(560,443	)		560,443			4.89
Exercised		-			(450,660	)		0.50
Forfeited/expired		21,468			(21,468	)		5.60
December 31, 2011		1,303,193			3,408,905		$	2.18
Granted under 2002 Plan		(280,000	)		280,000			4.75
Granted under 2012 Plan		(255,000	)		255,000			3.45
Exercised		-			(98,541	)		2.91
Forfeited/expired under 2002 Plan		-			(164,063	)		5.60
Added by 2012 Plan⁽¹⁾		4,000,000			-			-
Reduce options ungranted under 2002 Plan⁽²⁾		(1,023,193	)		-			-
December 31, 2012		3,745,000			3,681,301		$	1.96
Granted under 2012 Plan		(1,585,000	)		1,585,000			4.13
Exercised		-			(20,000	)		2.30
Forfeited/expired under 2002 Plan		-			(524,166	)		4.01
Forfeited/expired under 2012 Plan		155,000			(155,000	)		4.18
December 31, 2013		2,315,000			4,567,135		$	2.71

1)	During December 2012, the 2012 Equity Incentive Plan was approved by the BioTime Board of Directors making 4,000,000 common shares available for the grant of options. This plan was approved by the shareholders during October 2013.

2)	During September 2012, the 2002 Plan expired.

Additional information regarding options outstanding as of December 31, 2013 is as follows:

			Options Outstanding				Options Exercisable

Range of Exercise Prices	Number Outstanding		Weighted Avg. Remaining Contractual Life (years)		Weighted Avg. Exercise Price		Number Exercisable		Weighted Avg. Exercise Price

$0.50		1,970,400		0.77	$	0.50		1,970,400	$	0.50
2.30-8.58		2,596,735		4.86		4.39		1,277,262		4.54
$0.50-$8.58		4,567,135		3.10	$	2.71		3,247,662	$	2.09

Subsidiary Stock Option Plans

During 2013 Asterias adopted an Equity Incentive Plan that has substantially the same operative provisions as BioTime’s 2012 Plan except that it permits the sale or grant of up to 4,500,000 shares of Asterias common stock.

During 2011, BioTime’s subsidiary, LifeMap Sciences adopted a stock option plan that has substantially the same operative provisions as the BioTime 2002 Stock Option Plan. The LifeMap Sciences stock option plan authorized the sale of up to 8,000,000 shares of its common stock through the exercise of stock options or under restricted stock purchase agreements. During 2012, the LifeMap Sciences stock option plan was amended to reflect a 1 for 4 reverse stock split and a change in plan. As a result, the total number of shares that may be issued under the plan was adjusted to 1,842,168.

During 2010, BioTime’s subsidiaries OncoCyte, OrthoCyte, ReCyte Therapeutics, and BioTime Asia adopted stock option plans that have substantially the same operative provisions as the BioTime 2002 Stock Option Plan. The OncoCyte, OrthoCyte and ReCyte Therapeutics stock option plans each authorize the sale of up to 4,000,000 shares of the applicable subsidiary’s common stock through the exercise of stock options or under restricted stock purchase agreements. The BioTime Asia stock option plan authorizes the sale of up to 1,600 ordinary shares through the exercise of stock options or under restricted stock purchase agreements. Cell Cure Neurosciences' option plan authorizes the sale of 14,100 ordinary shares through the exercise of stock options.

			Options Outstanding				Options Exercisable

Range of Exercise Prices	Number Outstanding		Weighted Avg. Remaining Contractual Life (years)		Weighted Avg. Exercise Price		Number Exercisable		Weighted Avg. Exercise Price

$0.003-$0.75		5,256,226		5.96	$	0.36		4,089,035	$	0.35
1.00-1.75		2,072,342		5.86		1.57		571,073		1.43
2.05-2.34		4,080,000		6.39		2.25		1,294,062		2.16
27.00-42.02		7,840		6.80		37.35		7,840		37.35
$0.003-$42.02		11,416,408		6.10	$	1.28		5,962,010	$	0.89

The table above does not include the 50,000 options granted during 2013 under the Asterias Equity Incentive Plan for which the exercise prices had not been determined as of December 31, 2013. There were no other options granted under the other subsidiary stock option plans during the year ended December 31, 2013.

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

Cell Targeting, Inc. Asset Purchase [Abstract]

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64, 65, A240

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 93-6

-Paragraph 53

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Cell Targeting, Inc Asset Purchase

12 Months Ended

Dec. 31, 2013

Cell Targeting, Inc. Asset Purchase

11. Cell Targeting, Inc. Asset Purchase

On January 28, 2011, BioTime acquired substantially all of the assets of Cell Targeting, Inc. (“CTI”), a company that was engaged in research in regenerative medicine. The assets acquired consist primarily of patents, patent applications, and licenses to use certain patents. BioTime issued 261,959 of common shares and paid CTI $250,000 in cash to acquire the assets. The assets will be used by OncoCyte, which is developing cellular therapeutics for the treatment of cancer using vascular progenitor cells engineered to destroy malignant tumors.

The asset purchase is being accounted for as a business combination under the acquisition method of accounting. This means that even though BioTime did not directly assume and will not directly pay CTI’s debts or other liabilities, for financial accounting purposes CTI’s financial statements as of January 28, 2011, the date of the acquisition, are being consolidated with those of BioTime. In accordance with ASC 805, the total purchase consideration is allocated to the net tangible and identifiable intangible assets acquired and the CTI liabilities outstanding based on the estimated fair value of the assets and the amount of the liabilities as of January 28, 2011. BioTime amortizes intangible assets over their useful lives, which BioTime estimates to be 10 years.

The total purchase price of $2,550,000 is being allocated as indicated as follows:

Components of the purchase price:
BioTime common shares	$	2,300,000
Cash		250,000
Total purchase price	$	2,550,000

Preliminary allocation of purchase price:
Assets acquired and liabilities assumed:
Cash	$	3,150
Other current assets		2,443
Due from sellers		593,353
Intangible assets		2,419,287
Current liabilities		(468,233	)
Net assets acquired	$	2,550,000

The fair value of the shares issued was $8.78, the average closing price per share of BioTime common shares as reported on the NYSE MKT for the twenty (20) trading days immediately preceding the third trading day prior to the closing date, January 28, 2011.

Merger with Glycosan BioSystems, Inc

12 Months Ended

Dec. 31, 2013

Merger with Glycosan BioSystems, Inc. [Abstract]

Merger with Glycosan BioSystems, Inc.

12. Merger with Glycosan BioSystems, Inc.

On March 21, 2011, BioTime completed the acquisition of Glycosan BioSystems, Inc. (“Glycosan”) through a merger of Glycosan into OrthoCyte. Through the merger, OrthoCyte acquired all of Glycosan's assets, including manufacturing equipment, inventory, and technology licenses, and assumed Glycosan's obligations, which at March 18, 2011 totaled approximately $252,000 and primarily consisted of trade payables, accrued salaries, legal fees, and repayment of amounts advanced to Glycosan. BioTime issued 332,903 common shares and 206,613 warrants to purchase BioTime common shares in connection with the merger.

The merger is being accounted for under the acquisition method of accounting. In accordance with ASC 805, the total purchase consideration is allocated to the net tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of March 21, 2011. BioTime amortizes intangibles over their useful lives, which BioTime estimates to be 10 years. In accordance with ASC 805, BioTime does not amortize goodwill. The purchase price was allocated using the information currently available, and may be adjusted after obtaining more information regarding, among other things, asset valuations, liabilities assumed, and revisions of preliminary estimates.

The total purchase price for the merger of $3,554,879 is being allocated as indicated:

Components of the purchase price:
BioTime common shares	$	2,600,000
BioTime warrants		954,879
Total purchase price	$	3,554,879

Allocation of purchase price:
Assets acquired and liabilities assumed:
Cash	$	5,908
Other current assets		64,520
Property, plant and equipment, net		81,183
Intangible assets		3,592,039
Current liabilities		(188,771	)
Net assets acquired	$	3,554,879

The fair value of the shares issued was $7.81, the average closing price of BioTime common shares as reported on the NYSE MKT for the 10 trading days immediately preceding February 11, 2011, the date of the Merger Agreement. The fair value of the warrants issued was computed using a Black Scholes Merton option pricing model, which utilized the following assumptions: expected term of three years, which is equal to the contractual life of the warrants; risk-free rate of 1.12%; no expected dividend yield; 109.01% expected volatility; a stock price of $7.56; and an exercise price of $10.

Merger with XenneX, Inc

12 Months Ended

Dec. 31, 2013

Merger with XenneX, Inc. [Abstract]

Merger with XenneX, Inc.

13. Merger with XenneX, Inc.

On May 18, 2012, BioTime completed the acquisition of XenneX, Inc. (“XenneX”) through a merger of XenneX into LifeMap Sciences. Through the merger, XenneX stockholders received, in the aggregate, 1,429,380 shares of LifeMap Sciences common stock, which represented approximately 13.70% of the LifeMap Sciences common stock outstanding upon the closing of the transaction. XenneX shareholders also received approximately 448,429 BioTime common shares as part of the transaction. Through the merger, LifeMap Sciences acquired all of XenneX's assets, including cash, accounts receivables, prepaid assets, licenses, and assumed XenneX’s obligations, which at May 18, 2012 totaled approximately $572,826 and primarily consisted of trade payables, deferred subscription revenues, and distributions due to former XenneX shareholders.

The merger is being accounted for under the acquisition method of accounting. In accordance with ASC 805, the total purchase consideration is allocated to the net tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of May 18, 2012. BioTime amortizes intangibles over their useful lives, which BioTime estimates to be 10 years. In accordance with ASC 805, BioTime does not amortize goodwill. The purchase price was allocated using the information currently available, and may be adjusted after obtaining more information regarding, among other things, asset valuations, liabilities assumed, and revisions of preliminary estimates.

The total purchase price of $4,304,099 is being allocated as indicated:

Components of the purchase price:
BioTime common shares	$	1,802,684
LifeMap Sciences common shares		2,501,415
Total purchase price	$	4,304,099

Preliminary allocation of purchase price:
Assets acquired and liabilities assumed:
Cash	$	292,387
Other current assets		311,118
Intangible assets		4,273,420
Current liabilities		(294,572	)
Cash distributable to sellers		(278,254	)
Net assets acquired	$	4,304,099

The fair value of the BioTime shares issued was $4.02, the closing price as reported on the NYSE MKT on May 18, 2012, the date the merger was finalized. The fair value of the LifeMap Sciences shares issued was $1.75 as determined by negotiation between BioTime, LifeMap Sciences and XenneX and its stockholders and is consistent with an internal valuation analysis completed by BioTime.

Share Exchange and Contribution Agreement	12 Months Ended
Share Exchange and Contribution Agreement	Dec. 31, 2013
Share Exchange and Contribution Agreement [Abstract]
Share Exchange and Contribution Agreement	14. Share Exchange and Contribution Agreement On July 24, 2012, LifeMap Sciences entered into a Share Exchange and Contribution Agreement (the “LifeMap Agreement”) with Alfred D. Kingsley, the chairman of BioTime’s board of directors and a company that he controls, Greenway Partners, L.P. (“Greenway”), pursuant to which Mr. Kingsley and Greenway agreed to contribute to LifeMap Sciences, in the aggregate, BioTime common shares having an aggregate value of not less than $2,000,000 and not more than $3,000,000, determined as provided in the LifeMap Agreement, in exchange for shares of LifeMap Sciences common stock at an initial price of $1.75 per LifeMap Sciences share. Under the LifeMap Agreement, during July 2012 Mr. Kingsley and Greenway contributed 420,000 BioTime shares to LifeMap Sciences and received in exchange 1,143,864 shares of LifeMap Sciences common stock. During December 2012, Mr. Kingsley and Greenway contributed an additional 172,533 BioTime Shares to LifeMap Sciences and received in exchange 427,566 shares of LifeMap Sciences common stock. The number of shares of LifeMap Sciences common stock issued in exchange for the BioTime shares was determined by multiplying the number of BioTime shares contributed by the highest weighted average closing price per share on the NYSE MKT for any ten trading days during the period from July 1, 2012 through July 31, 2012, in the case of the shares exchanged during July, and during the period August 1, 2012 through December 15, 2012 in the case of the shares exchanged during December, and dividing that amount by $1.75, which was the Exchange Price per share of LifeMap Sciences common stock. See Note 8. As a result of this investment, and a sale of 142,857 additional shares of LifeMap Sciences for cash, our ownership dropped from 86.30% to 73.20% as of December 31, 2012. As of December 31, 2012, the 513,935 BioTime shares held by LifeMap Sciences are presented as treasury stock at a cost of $2,375,397. There has been no change in ownership during 2013. BioTime registered the BioTime Shares received by LifeMap Sciences during July 2012, and has agreed to register the additional shares received during December 2012, for sale under the Securities Act. In accordance with the License and Research Assignment Agreement dated May 14, 2012 between Yeda Research and Development Company, Ltd (“Yeda”) and BioTime in connection with the merger of XenneX, Inc. and LifeMap Sciences Yeda was entitled to receive additional shares of LifeMap Sciences common stock as a result of the issuance of additional shares of common stock by LifeMap Sciences during 2012 to permit Yeda to maintain their 3.75% ownership in the issued and outstanding LifeMap Sciences shares on a fully diluted basis. LifeMap Sciences issued Yeda 66,791 shares of LifeMap Sciences common stock with an estimated fair value of $117,000 under that provision of the License and Research Assignment Agreement.

Asset Contribution Agreement

12 Months Ended

Dec. 31, 2013

Asset Contribution Agreement [Abstract]

Asset Contribution Agreement

15. Asset Contribution Agreement

On January 4, 2013, BioTime and Asterias entered into an Asset Contribution Agreement with Geron Corporation (“Geron”) pursuant to which BioTime and Geron agreed to concurrently contribute certain assets to Asterias in exchange for shares of Asterias common stock. The transaction closed on October 1, 2013.

Transfer of BioTime Assets

Under the Asset Contribution Agreement, BioTime contributed to Asterias 8,902,077 BioTime common shares registered for re-sale with the SEC; warrants to subscribe for and purchase 8,000,000 additional BioTime common shares (the “BioTime Warrants”) exercisable for a period of five years at a price of $5.00 per share, subject to pro rata adjustment for certain stock splits, reverse stock splits, stock dividends, recapitalizations and other transactions; a 10% common stock interest in BioTime’s subsidiary OrthoCyte; a 6% ordinary stock interest in BioTime’s subsidiary Cell Cure Neurosciences; and a quantity of certain hES cell lines produced under “good manufacturing practices” sufficient to generate master cell banks, and non-exclusive, world-wide, royalty-free licenses to use those cell lines and certain patents pertaining to stem cell differentiation technology for any and all purposes.

In return, Asterias issued to BioTime 21,773,340 shares of its Series B common stock, par value $0.0001 per share (“Series B Shares”), and warrants to purchase 3,150,000 Series B Shares, exercisable for a period of three years from the date of issue at an exercise price of $5.00 per share. In addition, BioTime cancelled a loan of $5,000,000 outstanding from Asterias, related to cash financing provided by BioTime during 2013 prior to the closing of the asset contribution transaction under the Asset Contribution Agreement.

Because Asterias is a subsidiary of BioTime, transfer of assets from BioTime was accounted for as a transaction under common control. Non-monetary assets received by Asterias were recorded at their historical cost basis amounts with BioTime. Monetary assets were recorded at fair value. The difference between the value of assets contributed by BioTime and the fair value of consideration issued to BioTime was recorded as an additional contribution by BioTime, in additional paid-in capital.

The assets transferred by BioTime and the related consideration paid were recorded as follows:

Consideration transferred to BioTime:
Asterias Series B shares	$	52,164,568
Warrants to purchase Asterias Series B shares		2,012,481
Excess of contributed assets’ value over consideration		4,800,063
Total consideration issued	$	58,977,112

Assets transferred by BioTime:
BioTime common shares, at fair value	$	34,985,163
BioTime Warrants, at fair value		18,276,406
Cancellation of outstanding obligation to BioTime		5,000,000
Investment in affiliates, at cost		415,543
Geron asset acquisition related transaction costs paid by BioTime		300,000
Total assets transferred	$	58,977,112

The fair value of the Asterias Series B shares issued was estimated at $2.40 based on the Asterias enterprise value as determined on January 4, 2013, at the time the Asset Contribution Agreement was negotiated and executed by its parties, and as adjusted for subsequent changes in fair values of assets the parties agreed to contribute. The fair value of the warrants to purchase Asterias Series B shares was computed using a Black Scholes Merton option pricing model, which utilized the following assumptions: expected term equal to the contractual term of three years, which is equal to the contractual life of the warrants; risk-free rate of 0.63%; 0% expected dividend yield; 69.62% expected volatility based on the average historical common stock volatility of BioTime and Geron, which were used as Asterias’ common stock does not have a trading history; a stock price of $2.40; and an exercise price of $5.00.

BioTime common shares were valued using $3.93 the closing price per BioTime common shares on the NYSE MKT on October 1, 2013. The fair value of the BioTime Warrants was computed using a Black Scholes Merton option pricing model, which utilized the following assumptions: expected term equal to the contractual term of five years, which is equal to the contractual life of the warrants; risk-free rate of 1.42%; 0% expected dividend yield; 77.63% expected volatility based on historical common stock volatility of BioTime; a stock price of $3.93; and an exercise price of $5.00.

The investment in affiliates represents a non-monetary asset and was recorded at BioTime’s historical cost because BioTime is a common parent to Asterias and those affiliates.

Geron Assets Acquisition

Under the Asset Contribution Agreement, Geron contributed to Asterias certain patents, patent applications, trade secrets, know-how and other intellectual property rights with respect to the technology of Geron directly related to the research, development and commercialization of certain products and know-how related to hES cells; certain biological materials, reagents, laboratory equipment; as well as clinical trial documentation, files and data, primarily related to GRNOPC1 clinical trials for spinal cord injury and VAC1 clinical trials for acute myelogenous leukemia. Asterias assumed all obligations related to such assets that would be attributable to periods, events or circumstances after the Asset Contribution Agreement closing date, including those related to an appeal filed in the United States District Court in Civil Action No. C12-04813 (the “ViaCyte Appeal”) seeking the reversal of two adverse determinations by the United States Patent and Trademark Office’s Board of Patent Appeals and Interferences with respect to two patent applications in U.S. Patent Interference 105,734, involving US patent 7,510,876 (ViaCyte) and US patent application 11/960,477 (Geron), and U.S. Patent Interference 105,827 involving US patent 7,510,876 (ViaCyte) and US patent application 12/543,875 (Geron). Asterias also assumed the patent interferences upon which the ViaCyte Appeal is based, as well as certain oppositions filed by Geron against certain ViaCyte, Inc. patent filings in Australia and in the European Patent Office.

As consideration for the acquisition of assets from Geron, Asterias issued to Geron 6,537,779 shares of Series A common stock, par value $0.0001 per share (“Series A Shares”), which Geron had agreed to distribute to its stockholders, on a pro rata basis, subject to applicable legal requirements and certain other limitations (the “Series A Distribution”). Asterias is also obligated to distribute to the holders of its Series A Shares the 8,000,000 shares of BioTime Warrants contributed to Asterias by BioTime. Asterias will distribute the BioTime Warrants as promptly as practicable after notice from Geron that the Series A Distribution has been completed

In addition, Asterias agreed to bear certain transaction costs in connection with the Geron asset acquisition. Such transaction costs were allocated to acquisition of assets in the amount of $1,519,904 and issuance of equity in the amount of $541,800.

The assets contributed to Asterias by Geron did not include workforce or any processes to be applied to the patents, biological materials, and other assets acquired, and therefore did not constitute a business. Accordingly, the acquisition of the Geron assets has been accounted for as an acquisition of assets in accordance with the relevant provisions of Accounting Standards Codification (ASC) 805-50. Total consideration payable by Asterias, including transaction costs, has been allocated to the assets acquired based on relative fair values of those assets as of the date of the transaction, October 1, 2013, in accordance with ASC 820, Fair Value Measurement.

The assets acquired from Geron and the related consideration were recorded as follows:

Consideration paid to Geron:
Asterias Series A shares, net of share issuance costs of $541,800	$	15,121,222
Obligation to distribute BioTime Warrants		18,276,406
Transaction and other costs		1,519,904
Total consideration paid	$	34,917,532
Assets acquired from Geron (preliminary allocation):
Patents and other intellectual property rights related to hES cells	$	29,017,009
Deferred tax liability arising from difference in book versus tax basis on Geron intangible assets acquired		(11,558,243	)
IPR&D expensed upon acquisition		17,458,766
Total assets and in-process research and development acquired	$	34,917,532

The fair value of the Asterias Series A shares issued was estimated at $2.40 based on the estimated Asterias enterprise value as determined by parties at the time the Asset Contribution Agreement was negotiated and executed by its parties on January 4, 2013, as adjusted for subsequent changes in fair values of assets the parties agreed to contribute.

The fair value of the obligation to distribute BioTime Warrants equals the fair value of such warrants, which was computed as noted above under “Transfer of BioTime Assets.” Because the fair value of the BioTime Warrants is expected to always be equal to the fair value of the obligation to distribute them at any date on which those values are determined, the remeasurement of those values will not result in a charge or credit on the statement of operations.

The difference between the fair value of assets contributed by Geron and the fair value of consideration issued to Geron was recorded as an additional contribution by Geron, in additional paid-in capital, because the fair value of the assets transferred by Geron was more reliably determined.

Assets acquired from Geron consist primarily of patents and other intellectual property rights related to hES cells which Asterias intends to license to various parties interested in research, development and commercialization of hES cells technologies, and IPR&D, which includes biological materials, reagents, clinical trial documentation, files and data related primarily to certain clinical trials previously conducted by Geron, which Geron discontinued in November 2011.

Intangible assets related to IPR&D represent the value of incomplete research and development projects which the company intends to continue. In accordance with the accounting rules in ASC 805, such assets, when acquired in conjunction with acquisition of a business, are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts and are capitalized as an asset. If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. However, when acquired in conjunction with an acquisition of assets that do not constitute a business (such as the acquisition of assets from Geron), in accordance with the accounting rules in ASC 805-50, such intangible assets related to IPR&D are expensed upon acquisition.

The values of the acquired assets were estimated at October 1, 2013 based upon a preliminary review of those assets which took into account factors such as the condition of the cells, cell lines and other biological materials being contributed, the stage of development of particular technology and product candidates related to patents, patent applications, and know-how, the intended use of these assets and the priority assigned to the development of product candidates to which those assets relate, and the assessment of the estimated useful lives of patents. The amounts allocated to patents and other intellectual property rights that Asterias intends to license were capitalized as intangible assets and are being amortized over an estimated useful life period of 10 years. The amounts allocated to IPR&D were expensed at the time of acquisition of the related assets in accordance with the requirements of ASC 805-50. The allocation was based on the relative fair value of assets eligible for capitalization and the fair value of assets representing IPR&D before assessing the deferred tax liability arising from the difference in book versus tax basis on Geron intangible assets acquired, which management estimated to be approximately equal. Accordingly, $17,458,766 was capitalized as of December 31, 2013, and $17,458,766 was expensed. These amounts are preliminary as management has not yet completed a detailed assessment and valuation of the acquired assets. Such assessment and valuation is expected to be completed during the quarter ending June 30, 2014. Accordingly, the amounts included in capitalized intangible assets and expensed IPR&D as of December 31, 2013 are subject to adjustments which could be material.

Asterias is also obligated to pay Geron royalties on the sale of products, if any, that are commercialized in reliance upon patents acquired from Geron, at the rate of 4% of net sales.

Stock and Warrant Purchase Agreement with Romulus

On January 4, 2013, in connection with entering into the Asset Contribution Agreement, Asterias entered into a Stock and Warrant Purchase Agreement with Romulus Films, Ltd (“Romulus”) pursuant to which Romulus agreed to purchase 2,136,000 Series B Shares and warrants to purchase 350,000 additional Series B Shares for $5,000,000 in cash upon the consummation of the acquisition of assets under the Asset Contribution Agreement. On October 1, 2013, the shares and warrants were issued in exchange for $5,000,000 in cash.

Commitments and Contingencies

12 Months Ended

Dec. 31, 2013

Commitments and Contingencies [Abstract]

Commitments and Contingencies

16. Commitments and Contingencies

BioTime had no fixed, non-cancelable contractual obligations as of December 31, 2013, with the exception of office and laboratory facility operating leases.

BioTime Leases

BioTime leases office and research laboratory space in Alameda, California. Base monthly rent is $30,752 from December 2013 and will increase by three percent each year. In addition to the base rent, BioTime pays a pro rata share of real property taxes and certain costs associated to the operation and maintenance of the building in which the leased premises are located.

BioTime also leases an office and research facility located in La Jolla, California. The lease is for a term one year plus one half month commencing October 15, 2013. BioTime pays base rent of $4,330 per month, plus operational costs of maintaining the leased premises.

BioTime also currently pays $5,050 per month for the use of office space in New York City, which is made available to BioTime by one of its directors at his cost for use in conducting meetings and other business affairs.

Asterias Leases

BioTime leases an office and research facility located in Menlo Park, California for use by Asterias. The lease is for a term of three years commencing January 7, 2013. Base rent is $31,786 per month, plus real estate taxes and certain costs of maintaining the leased premises.

Asterias has entered into a lease for an office and research facility located in Fremont, California. The lease is for a term of 96 months and the estimated term commencement date is October 1, 2014. Asterias will pay base monthly rent of $99,000 during the first 12 months commencing on the term commencement date, except that during the first 15 months of the lease term, Asterias will pay base rent on only 22,000 square feet rather than 44,000 square feet provided that Asterias is not in default in performing its obligations under the lease beyond any notice and cure periods. Base monthly rent will increase by approximately 3% annually. In addition to monthly base rent Asterias will pay all real estate taxes, insurance, a management fee in the amount of 3% of base rent, and the cost of maintenance, repair and replacement of the leased premises. During the first 15 months of the lease term, Asterias will pay only 50% of the real estate taxes assessed on the premises provided that Asterias is not in default in performing its obligations under the lease beyond any notice and cure periods. However, if any improvements or alterations to the premises that Asterias constructs or adds are assessed for real property tax purposes at a valuation higher than the valuation of the improvements on the Premises on the date signed the lease, Asterias will pay 100% of the taxes levied on the excess assessed valuation.

ESI Lease

ESI had leased approximately 125 square meters of laboratory space in Singapore under a lease that expired on February 28, 2014. Base monthly rent under the Singapore laboratory lease was S$11,000 (approximately US$8,700). In addition to base rent, ESI paid a pro rata share of real property taxes and certain costs related to the operation and maintenance of the building in which the leased premises were located. ESI will continue to pursue our ongoing plans to establish new laboratory facilities in Singapore for manufacturing and distribution of ESI BIO research products in Asia.

Cell Cure Lease

Cell Cure Neurosciences leases approximately 290 square meters of office and laboratory space in Hadassah Ein Kerem, in Jerusalem, Israel under a lease that expires on June 1, 2014. Base monthly rent for that facility is approximately ILS 33,000 (approximately US$9,500). In addition to base rent, Cell Cure Neurosciences pays a pro rata share of real property taxes and certain costs related to the operation and maintenance of the building in which the leased premises are located. Cell Cure Neurosciences will be liable for ILS 820,000 (approximately US$236,000) in improvement costs if the company renews the lease agreement for five additional years.

LifeMap Lease

LifeMap Sciences office space in Tel Aviv, Israel under a lease expiring on May 31, 2015. Base monthly rent under the lease from July 2013 is ILS 25,889 (approximately US$7,400) per month. In addition to base rent, LifeMap Sciences pays a pro rata share of real property taxes and certain costs related to the operation and maintenance of the building in which the leased premises are located. LifeMap Sciences also leases several parking spots.

LifeMap Sciences leases approximately office space in Hong Kong under a lease that commenced on December 1, 2013 and expires on November 30, 2015. Base monthly rent under the lease is HK$7,500 (approximately US $970) per month. In addition to base rent, LifeMap pays certain costs related to the operation of the building in which the leased premises are located.

LifeMap also leases office space in Marshfield, Massachusetts under a lease that expires on September 30, 2015. Base monthly rent under the lease is $1,082 per month.

Rent expenses totaled $1,599,725, $1,178,840, and $1,058,170 for the years ended December 31, 2013, 2012, and 2011, respectively. Remaining minimum annual lease payments under the various operating leases for the year ending after December 31, 2013 are as follows:

Year Ending December 31,	Minimum lease payments
2014		1,188,316
2015		1,973,845
2016		1,266,825
2017		1,271,160
2018		1,308,120
Thereafter		5,262,840
Total		12,271,106

The entire disclosure for commitments and contingencies.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 14

-Paragraph 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 9, 10, 11, 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Income Taxes

12 Months Ended

Dec. 31, 2013

Income Taxes [Abstract]

Income Taxes

17. Income Taxes

The primary components of the net deferred tax liabilities at December 31, 2013 and 2012 were as follows:

	2013			2012
Deferred tax assets/(liabilities):
Net operating loss carryforwards	$	46,711,000		$	36,111,000
Research & development and other credits		2,329,000			1,856,000
Patents and licenses		(11,934,000	)		(1,066,000	)
Other, net		737,000			-
Total		37,843,000			36,901,000
Valuation allowance		(46,121,000	)		(36,901,000	)
Net deferred tax liabilities	$	(8,278,000	)	$	-

Income taxes differed from the amounts computed by applying the U.S. federal income tax of 34% to pretax losses from operations as a result of the following:

	Year Ended December 31,
	2013	2012	2011

Computed tax benefit at federal statutory rate	(34%)	(34%)	(34%)
Permanent differences	15%	3%	(1%)
Losses for which no benefit has been recognized	18%	28%	41%
State tax benefit, net of effect on federal income taxes	(4%)	-	(6%)
Foreign rate differential	(1%)	3%	-
	(6%)	0%	0%

As of December 31, 2013, BioTime has net operating loss carryforwards of approximately $99,100,000 for federal and $70,200,000 for state tax purposes, which expire through 2033. In addition, BioTime has tax credit carryforwards for federal and state tax purposes of $1,076,000 and $1,253,000, respectively, which expire through 2033. As of December 31, 2013, BioTime’s subsidiaries have foreign net operating loss carryforwards of approximately $48,400,000 which carry forward indefinitely.

A deferred income tax benefit of approximately $3,280,000 was recorded for the year ended December 31, 2013, of which approximately $2,800,000 was related to federal and $480,000 was related to state taxes. No tax benefit has been recorded through December 31, 2012 because of the net operating losses incurred and a full valuation allowance has been provided. A valuation allowance is provided when it is more likely than not that some portion of the deferred tax assets will not be realized. BioTime established a valuation allowance for all periods presented due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets.

Internal Revenue Code Section 382 places a limitation (“Section 382 Limitation”) on the amount of taxable income that can be offset by net operating loss (“NOL”) carryforwards after a change in control (generally greater than 50% change in ownership within a three-year period) of a loss corporation. California has similar rules. Generally, after a control change, a loss corporation cannot deduct NOL carryforwards in excess of the Section 382 Limitation. Due to these “change in ownership” provisions, utilization of the NOL and tax credit carryforwards may be subject to an annual limitation regarding their utilization against taxable income in future periods.

BioTime files an income tax return in the U.S. federal jurisdiction, and may file income tax returns in various U.S. states and foreign jurisdictions. Generally, BioTime is no longer subject to income tax examinations by major taxing authorities for years before 2010.

BioTime may be subject to potential examination by U.S. federal, U.S. states or foreign jurisdiction authorities in the areas of income taxes. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with U.S. federal, U.S. state and foreign tax laws. BioTime's management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 136, 172

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 43, 44, 45, 46, 47, 48, 49

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Segment Information	12 Months Ended
Segment Information	Dec. 31, 2013
Segment Information [Abstract]
Segment Information	18. Segment Information BioTime’s executive management team represents its chief decision maker. To date, BioTime’s management has viewed BioTime’s operations as one segment that includes, the research and development of therapeutic products for oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer, and hydrogel products that may be used in surgery, and products for human embryonic stem cell research. As a result, the financial information disclosed materially represents all of the financial information related to BioTime’s sole operating segment.

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

Enterprise wide Disclosures [Abstract]

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 131

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 32

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 29

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 34

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 35

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 42

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 40

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 31

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 41

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 33

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

+ Details

Enterprise-wide Disclosures

12 Months Ended

Dec. 31, 2013

Enterprise-wide Disclosures

19. Enterprise-wide Disclosures

Geographic Area Information

Revenues, including license fees, royalties, grant income, and other revenues by geographic area are based on the country of domicile of the licensee or grantor.

Geographic Area	Revenues for the Year ending December 31,
	2013		2012		2011
Domestic	$	2,106,161	$	2,529,669	$	3,059,810
Asia		2,328,175		1,385,658		1,374,349
Total revenues	$	4,434,336	$	3,915,327	$	4,434,159

Major Sources of Revenues

BioTime has two major customers and two major grants comprising significant amounts of total revenues.

All of BioTime’s royalty revenues were generated through sales of Hextend^® by Hospira in the U.S. and by CJ in the Republic of Korea. BioTime also earned license fees from CJ and Summit.

BioTime was awarded a $4,721,706 grant for a stem cell research project related to its PureStem^™ technology by CIRM in April 2009. The CIRM grant covered the period of September 1, 2009 through August 31, 2012. BioTime recognized $0 and $1,047,106 as revenues as of December 31, 2013 and December 31, 2012, respectively. The final quarterly installment of $392,664 was collected in February 2013.

During 2013, BioTime received $111,691 and recognized as revenues $150,239 of a $335,900 grant awarded by the National Institutes of Health (“NIH”). During 2012, BioTime received $45,645 and recognized as revenues $47,507. The grant period commenced on September 30, 2011 and will end on September 29, 2014. As of December 31, 2013, $110,237 remained available for funding under the grant.

During 2013, grant income also included awards from a separate grant awarded by the NIH in 2013 in the amount of $71,355, and grants from other sources in the amount of $1,333,901 recognized through Cell Cure Neurosciences, $13,838 through Life Map Sciences, Ltd., and $3,996 through ES Cell International. During 2012, grant income also included $1,109,699 recognized through Cell Cure Neurosciences and $18,145 through Life Map Sciences, Ltd.

During 2013, BioTime received $1,082,077 and recognized $609,314 (net of $707,695 in royalty and commission fees) in net subscription and advertisement revenues through LifeMap Sciences. During 2012, BioTime received $1,222,516 and recognized $373,798 (net of $379,098 in royalty and commission fees) in net subscription and advertisement revenues through LifeMap Sciences.

The following table shows the relative portions of BioTime’s royalty and license fee revenues paid by Hospira, CJ, and Summit that were recognized during the years ended December 31, 2013, 2012, and 2011, subscription and advertisement revenues, and grant income recognized during the same periods with respect to grants provided by the office of the Chief of Scientist of Israel (“OCS”), the NIH (SBIR) and CIRM:

Sources of Revenues	% of Total Revenues for Year ended December 31,
	2013			2012			2011
Hospira		6.5	%		11.0	%		14.2	%
CJ		1.7	%		2.9	%		3.5	%
Summit		20.3	%		3.7	%		3.3	%
CIRM		0.0	%		26.7	%		35.4	%
NIH		5.0	%		1.2	%		0.6	%
OCS		27.9	%		26.0	%		23.0	%
Subscription and Advertising (various customers)		38.6	%		28.5	%		20.0	%

Selected Quarterly Financial Information (UNAUDITED)

12 Months Ended

Dec. 31, 2013

Selected Quarterly Financial Information (UNAUDITED) [Abstract]

Selected Quarterly Financial Information (UNAUDITED)

20. Selected Quarterly Financial Information (UNAUDITED)

	First Quarter			Second Quarter			Third Quarter			Fourth Quarter
Year Ended December 31, 2013
Revenues, net	$	431,724		$	1,035,514		$	507,384		$	1,670,063
Acquired in-process research and development⁽¹⁾		-			-			-			17,458,766
Operating expenses		8,811,633			9,151,965			10,709,337			13,504,740
Loss from operations		(8,379,909	)		(8,116,451	)		(10,201,953	)		(29,243,443	)
Net loss attributable to BioTime, Inc.⁽²⁾		(7,719,263	)		(7,549,765	)		(9,003,168	)		(19,612,314	)

Basic and diluted net loss per share		(0.15	)		(0.14	)		(0.16	)		(0.35	)

Year Ended December 31, 2012
Revenues, net	$	631,946		$	949,746		$	833,817		$	1,065,547
Operating expenses		6,547,486			7,029,077			6,780,375			8,124,795
Loss from operations		(5,915,540	)		(6,079,331	)		(5,946,558	)		(7,059,248	)
Net loss attributable to BioTime, Inc.		(4,973,342	)		(5,457,222	)		(4,958,014	)		(6,037,125	)
Basic and diluted net loss per share		(0.10	)		(0.11	)		(0.10	)		(0.12	)

(1)	Includes IPR&D expenses related to intangible assets acquired by Asterias from Geron under the Asset Contribution Agreement. IPR&D represents the value of incomplete research and development projects which Asterias intends to continue. See Notes 2 and 15.

(2)	Net of $3,280,695 income tax benefits in fourth quarter.

Pro Forma Financial Information for Fiscal Years Ended December 31, 2013 and 2012 (UNAUDITED)

The entire disclosure for the quarterly financial data in the annual financial statements. The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.

+ References+ Details

Pro Forma Financial Information for Fiscal Years Ended December 31, 2013 and 2012 (UNAUDITED)

12 Months Ended

Dec. 31, 2013

Pro Forma Financial Information for Fiscal Years Ended December 31, 2013 and 2012 (UNAUDITED)

21. Pro Forma Financial Information for Fiscal Years Ended December 31, 2013 and 2012 (UNAUDITED)

The following unaudited pro forma information gives effect to the merger with XenneX and asset acquisition through the Asset Contribution Agreement as if the transactions took place on January 1, 2012. The pro forma information does not necessarily reflect the results of operations that would have occurred had the entities been a single company during the periods presented.

	Year Ended December 31,
	2013			2012

Revenues	$	4,434,336		$	4,206,973
(Loss) available to common shareholders⁽¹⁾	$	(26,424,069	)	$	(38,781,953	)
(Loss) per common share – basic	$	(0.49	)	$	(0.78	)
(Loss) per common share – diluted	$	(0.49	)	$	(0.78	)

(1)	For 2012, includes $17,458,766 of IPR&D acquired under the Asset Contribution Agreement which was completed on October 1, 2013. See Note 15.

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2013
Subsequent Events [Abstract]
Subsequent Events	22. Subsequent Events Sale of Common Shares After December 31, 2013, BioTime and three of its subsidiaries, OncoCyte, LifeMap Sciences, and Cell Cure Neurosciences, raised $8,474,005 through sales of 2,240,060 BioTime common shares in “at-the-market” transactions through Cantor Fitzgerald & Co. (“Cantor”), as the sales agent. The BioTime common shares sold by the subsidiaries had been previously contributed to the subsidiaries by BioTime in exchange for subsidiary capital stock. The proceeds from the sale of BioTime common shares by BioTime subsidiaries belong to those subsidiaries. Research Grant On February 24, 2014, BioTime was awarded a $270,262 SBIR Phase 1 Small Business Grant from the National Institute of General Medical Sciences (NIGMS) at the National Institutes of Health (NIH) for a research and development project. Sale of Preferred Stock On March 4, 2014, BioTime raised $3,500,000 through the sale of 70,000 shares of Series A Convertible Preferred Stock (“Series A Preferred Stock”) pursuant to a series of Series A Convertible Preferred Stock Purchase Agreements of like terms. In connection with the sale of the Series A Preferred Stock, BioTime also entered into an Option Agreement with each purchaser of Series A Preferred Stock entitling them to exchange their shares of Series A Preferred Stock for shares of common stock of BioTime’s subsidiary LifeMap Sciences. held by BioTime, at the rate of 12.5 shares of LifeMap Sciences common stock for each share of BioTime Series A Preferred Stock. The exchange ratio is subject to adjustment in the event of a stock split, stock dividend, stock combination, or similar event with respect to LifeMap Sciences common stock. The option will expire if not exercised by March 4, 2019. BioTime’s Board of Directors designated 300,000 preferred shares as shares of Series A Convertible Preferred Stock. The Series A Preferred Stock carries a cumulative annual 3% preferred dividend or $1.50 per share which shall accrue on June 30 and December 31 accrued on June 30, and December 31 of each year regardless of whether declared by the Board of Directors and shall be paid, from funds legally available for such purpose, in two semi-annual installments on January 31 and July 31 of each year, or if such day is not a business day, on the next business day. Any dividends or distributions declared and paid or distributed with respect to common shares and any other stock ranking as “junior stock” to the Series A Preferred Stock (other than dividends and distributions of shares of junior stock resulting in an adjustment of the conversion price) shall likewise be declared and paid or distributed to holders of Series A Preferred Stock such that all holders of common shares, other junior stock if any, and Series A Preferred Stock shall receive such dividends or distributions in proportion to the number of common shares and shares of any other junior stock that would be held by each such holder if all shares of Series A Preferred Stock were converted to common shares (or such other series of junior stock, if applicable) at the conversion price in effect as of the record date for the determination of holders of common shares (or such other series of junior stock, if applicable) entitled to receive the dividend or distribution. Each share of Series A Preferred Stock is convertible, at the election of the holder, into BioTime common shares at a conversion price of $4.00 per share, a current conversion ratio of 12.5 common shares for each share of Series A Preferred Stock. All outstanding Series A Preferred Stock will automatically be converted into common shares on March 4, 2019, or if holders of a majority of the outstanding shares of Series A Preferred Stock, voting as a class, approve or consent to a conversion. The conversion price is subject to prorata adjustment in the event of a subdivision or reclassification of the common shares into a greater number of shares, a stock dividend paid in common shares, or a stock combination or reclassification of the common shares into a smaller number of shares. In the event of a liquidation or dissolution of BioTime, holders of Series A Preferred Stock will be entitled to receive payment of any accrued but unpaid preferred dividends before any assets may be distributed to holders of common shares and any other capital stock ranking junior to the Series A Preferred Stock with respect to the distribution of assets upon liquidation. After payment of the accrued dividends, the Series A Preferred Stock will participate with the common shares and other capital stock ranking as parity stock or junior stock with respect to the Series A Preferred Stock in the distribution of any assets available to shareholders, as if the Series A Preferred Stock was then converted into common shares. The Series A Preferred Stock will be entitled to vote with common shares on all matters submitted to common shareholders for approval. Each share of Series A Preferred Stock will be entitled to a number of votes equal to the number common shares into which it could then be converted at the record date for the determination of the shareholders entitled to vote on such matters, or, if no such record date is established, at the date such vote is taken or any written consent of shareholders is solicited. The Series A Preferred Stock will be entitled to vote as a separate class only as to the following matters: (i) the creation of any preferred stock ranking as senior to the Series A Preferred Stock with respect to the payment of dividends, liquidation preferences or voting rights; (ii) a repurchase of any common shares or other stock ranking junior to the Series A Preferred Stock, except shares issued pursuant to or in connection with a compensation or incentive plan or agreement approved by BioTime’s Board of Directors for any officers, directors, employees or consultants of the company; (ii) any sale, conveyance, or other disposition of all or substantially all of BioTime's property or business, or any liquidation or dissolution of the company, or a merger into or consolidation with any other corporation (other than a wholly-owned subsidiary corporation), or any one or series of related transactions in which more than 50% of the voting power of BioTime is disposed of, unless upon consummation of such transaction the holders of Series A Preferred Stock would receive a distribution on account of each share of Series A Preferred Stock an amount of cash or other property or both having a value at least equal to the value of any cash, property, or both to which holders of common shares would be entitled to receive, plus the amount of any accrued but unpaid preferred dividends; (iii) any adverse change in the rights, preferences and privileges of the Series A Preferred Stock; or (iv) any amendment of BioTime’s Articles of Incorporation or Bylaws that results in any adverse change in the rights, preferences or privileges of the Series A Preferred Stock; provided, that those voting rights shall not restrict or limit the rights and powers of BioTime’s Board of Directors to fix by resolution the rights, preferences, and privileges of, and restrictions and limitations on, stock ranking as parity stock or junior stock to Series A Preferred Stock. These consolidated financial statements were approved by management and the Board of Directors, and were issued on March 17, 2014. Subsequent events have been evaluated through that date.

Summary of Significant Accounting Policies (Policies)	12 Months Ended
Summary of Significant Accounting Policies (Policies)	Dec. 31, 2013
Summary of Significant Accounting Policies [Abstract]
Use of estimates	Use of estimates – The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Revenue recognition	Revenue recognition – BioTime complies with SEC Staff Accounting Bulletin guidance on revenue recognition. Royalty revenues consist of product royalty payments. License fee revenues consist of fees under license agreements and are recognized when earned and reasonably estimable and also include subscription and advertising revenue from our online databases based upon respective subscription or advertising periods. BioTime recognizes revenue in the quarter in which the royalty reports are received, rather than the quarter in which the sales took place. When BioTime is entitled to receive up-front nonrefundable licensing or similar fees pursuant to agreements under which BioTime has no continuing performance obligations, the fees are recognized as revenues when collection is reasonably assured. When BioTime receives up-front nonrefundable licensing or similar fees pursuant to agreements under which BioTime does have continuing performance obligations, the fees are deferred and amortized ratably over the performance period. If the performance period cannot be reasonably estimated, BioTime amortizes nonrefundable fees over the life of the contract until such time that the performance period can be more reasonably estimated. Milestone payments, if any, related to scientific or technical achievements are recognized in income when the milestone is accomplished if (a) substantive effort was required to achieve the milestone, (b) the amount of the milestone payment appears reasonably commensurate with the effort expended, and (c) collection of the payment is reasonably assured. Grant income and the sale of research products are recognized as revenue when earned. Revenues from the sale of research products are primarily derived from the sale of hydrogels and stem cell products.
Cash and cash equivalents	Cash and cash equivalents – BioTime considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.
Accounts receivable and allowance for doubtful accounts	Accounts receivable and allowance for doubtful accounts - Trade accounts receivable and grants receivable are presented in the prepaid expenses and other current assets line item of the consolidated balance sheet. Total trade receivables amounted to approximately $575,900 and $395,000 and grants receivable amounted to approximately $539,300 and $1,059,000 as of December 31, 2013 and 2012, respectively. Some of these amounts are deemed uncollectible; as such BioTime recognized allowance for doubtful accounts in the amount of $116,816 as of December 31, 2013 and 2012. BioTime evaluates the collectability of its receivables based on a variety of factors, including the length of time receivables are past due and significant one-time events and historical experience. An additional reserve for individual accounts will be recorded if BioTime becomes aware of a customer’s inability to meet its financial obligations, such as in the case of bankruptcy filings or deterioration in the customer’s operating results or financial position. If circumstances related to customers change, estimates of the recoverability of receivables would be further adjusted.
Concentrations of credit risk	Concentrations of credit risk – Financial instruments that potentially subject BioTime to significant concentrations of credit risk consist primarily of cash and cash equivalents. BioTime limits the amount of credit exposure of cash balances by maintaining its accounts in high credit quality financial institutions. Cash equivalent deposits with financial institutions may occasionally exceed the limits of insurance on bank deposits; however, BioTime has not experienced any losses on such accounts.
Inventory	Inventory – Inventories are stated at the lower of cost or market. Cost, which includes amounts related to materials, labor, and overhead, is determined in a manner which approximates the first-in, first-out (“FIFO”) method.
Equipment	Equipment – Equipment is stated at cost. Equipment is being depreciated using the straight-line method over a period of 36 to 120 months. See Note 4.
Intangible assets	Intangible assets – Intangible assets with finite useful lives are amortized over estimated useful lives and intangible assets with indefinite lives are not amortized but rather are tested at least annually for impairment. Acquired in-process research and development intangible assets are accounted for depending on whether they were acquired as part of an acquisition of a business, or assets that do not constitute a business. When acquired in conjunction with acquisition of a business, these assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts and are capitalized as an asset. If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. However, when acquired in conjunction with an acquisition of assets that do not constitute a business (such as the acquisition of assets from Geron), in accordance with the accounting rules in ASC 805-50, such intangible assets related to in-process research and development (“IPR&D”) are expensed upon acquisition.
Treasury stock	Treasury stock – BioTime accounts for BioTime common shares issued to subsidiaries for future potential working capital needs as treasury stock on the consolidated balance sheet. BioTime has the intent and ability to register any unregistered shares to support the marketability of the shares.
Warrants to purchase common stock	Warrants to purchase common stock – BioTime generally accounts for warrants issued in connection with equity financings as a component of equity. None of the warrants issued by BioTime as of December 31, 2013 include a conditional obligation to issue a variable number of shares; nor was there a deemed possibility that BioTime may need to settle the warrants in cash. If BioTime were to issue warrants with a conditional obligation to issue a variable number of shares or with the deemed possibility of a cash settlement, BioTime would record the fair value of the warrants as a liability at each balance sheet date and record changes in fair value in other income and expense in the consolidated statements of operations.
Cost of sales	Cost of sales – BioTime accounts for the cost of research products acquired for sale and any royalties paid as a result of any revenues in accordance with the terms of the respective licensing agreements as cost of sales on the consolidated statement of operations.
Patent costs	Patent costs – Costs associated with obtaining patents on products or technology developed are expensed as general and administrative expenses when incurred. This accounting is in compliance with guidance promulgated by the Financial Accounting Standards Board (the “FASB”) regarding goodwill and other intangible assets.
Reclassification	Reclassification – Certain prior year amounts have been reclassified to conform to the current year presentation.
Research and development	Research and development – BioTime complies with FASB requirements governing accounting for research and development costs. Research and development costs are expensed when incurred, and consist principally of salaries, payroll taxes, consulting fees, research and laboratory fees, and license fees paid to acquire patents or licenses to use patents and other technology from third parties.
Foreign currency translation gain/(loss) and comprehensive loss	Foreign currency translation gain/(loss) and comprehensive loss – In countries in which BioTime operates, and the functional currency is other than the U.S. dollar, assets and liabilities are translated using published exchange rates in effect at the consolidated balance sheet date. Revenues and expenses and cash flows are translated using an approximate weighted average exchange rate for the period. Resulting translation adjustments are recorded as a component of accumulated other comprehensive income on the consolidated balance sheet. For the fiscal years ended December 31, 2013 and 2012, comprehensive loss includes gain of $122,469 and $63,179, respectively which is largely from foreign currency translation. For the fiscal year ended December 31, 2013 and 2012, foreign currency transaction loss amounted to $133,479 and $34,233, respectively.
Income taxes	Income taxes – BioTime accounts for income taxes in accordance with GAAP requirements, which prescribe the use of the asset and liability method, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and rates in effect. Valuation allowances are established when necessary to reduce deferred tax assets when it is more likely than not that a portion or all of the deferred tax assets will not be realized. The FASB guidance also prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not sustainable upon examination by taxing authorities. For 2013, Asterias will file a separate U.S. federal and state income tax returns but effectively BioTime will combine Asterias' tax provision with BioTime's. BioTime recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties as of December 31, 2013 and 2012. BioTime files its income tax returns in the U.S. federal and various state and local and foreign jurisdictions. Generally, BioTime is no longer subject to income tax examinations by major taxing authorities for years before 2010. Any potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with U.S. federal, state and local and foreign tax laws. Management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.
Stock-based compensation	Stock-based compensation – BioTime adopted accounting standards governing share-based payments, which require the measurement and recognition of compensation expense for all share-based payment awards made to directors and employees, including employee stock options, based on estimated fair values. In March 2005, the SEC issued additional guidelines which provide supplemental implementation guidance for valuation of share-based payments. BioTime has applied the provisions of this guidance in such valuations as well. Consistent with those guidelines, BioTime utilizes the Black-Scholes Merton option pricing model. BioTime's determination of fair value of share-based payment awards on the date of grant using that option-pricing model is affected by BioTime's stock price as well as by assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, BioTime's expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. The expected term of options granted is derived from historical data on employee exercises and post-vesting employment termination behavior. The risk-free rate is based on the U.S. Treasury rates in effect during the corresponding period of grant. Although the fair value of employee stock options is determined in accordance with recent FASB guidance, changes in the subjective assumptions can materially affect the estimated value.
Impairment of long-lived assets	Impairment of long-lived assets – BioTime’s long-lived assets, including intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. If an impairment indicator is present, BioTime will evaluate recoverability by a comparison of the carrying amount of the assets to future undiscounted net cash flows expected to be generated by the assets. If the assets are impaired, the impairment will be recognized and is measured by the amount by which the carrying amount exceeds the estimated fair value of the assets.
Deferred license and consulting fees	Deferred license and consulting fees – Deferred license and consulting fees consist of the value of warrants issued to third parties for services, and deferred license fees paid to acquire rights to use the proprietary technologies of third parties. The value of the warrants is being amortized over the period the services are being provided, and the license fees are being amortized over the estimated useful lives of the licensed technologies or licensed research products. See Note 6.
Loss per share	Loss per share – Basic net loss per share is computed by dividing net loss attributable to BioTime by the weighted-average number of common shares outstanding for the period. Diluted net loss per share reflects the weighted-average number of common shares outstanding plus the potential effect of dilutive securities or contracts which are convertible to common shares, such as options and warrants (using the treasury stock method) and shares issuable in future periods, except in cases where the effect would be anti-dilutive. Diluted loss per share for years ended December 31, 2013, 2012, and 2011 excludes any effect from 10,697,715 treasury shares, 4,567,135 options and 9,751,615 warrants, 1,800,109 treasury shares, 3,681,301 options and 556,613 warrants, and 1,286,174 treasury shares, 3,408,905 options and 636,613 warrants, respectively.
Fair value of financial instruments	Fair value of financial instruments – The fair value of BioTime’s assets and liabilities, which qualify as financial instruments under FASB guidance regarding disclosures about fair value of financial instruments, approximate the carrying amounts presented in the accompanying consolidated balance sheets.
Effect of recently issued and recently adopted accounting pronouncements	Effect of recently issued and recently adopted accounting pronouncements – There are no recently issued accounting standards which are not yet effective which BioTime believes would materially impact the consolidated financial statements.

Organization and Basis of Presentation (Tables)

12 Months Ended

Dec. 31, 2013

Organization and Basis of Presentation [Abstract]

BioTime's ownership of outstanding shares of its subsidiaries

Subsidiary	BioTime Ownership	Country
Asterias Biotherapeutics, Inc.	71.6%⁽¹⁾	USA
ReCyte Therapeutics, Inc.	94.8%	USA
OncoCyte Corporation	75.3%	USA
OrthoCyte Corporation	100%	USA
ES Cell International Pte Ltd.	100%	Singapore
BioTime Asia, Limited	81%	Hong Kong
Cell Cure Neurosciences Ltd.	62.5%	Israel
LifeMap Sciences, Inc.	73.2%	USA
LifeMap Sciences, Ltd.	(2)	Israel

(1)

(2)	LifeMap Sciences, Ltd. is a wholly-owned subsidiary of LifeMap Sciences, Inc.

Equipment, furniture and fixtures

The tabular disclosure of the effects of any changes in a parent's ownership interest in a subsidiary on the equity attributable to the parent if the ownership interests in a subsidiary changes during the period. The changes represented by this element did not result in the deconsolidation of the subsidiary.

+ References+ Details

Equipment (Tables)

12 Months Ended

Dec. 31, 2013

Equipment [Abstract]

At December 31, 2013 and December 31, 2012, equipment, furniture and fixtures were comprised of the following:

	2013			2012
Equipment, furniture and fixtures	$	4,431,586		$	2,098,812
Accumulated depreciation		(1,433,853	)		(750,258	)
Equipment net of accumulated depreciation	$	2,997,733		$	1,348,554

Intangible assets future amortization expense

Tabular disclosure of the useful life and salvage value of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.

+ References+ Details

Intangible assets (Tables)

12 Months Ended

Dec. 31, 2013

Intangible assets [Abstract]

Intangible assets

At December 31, 2013 and December 31, 2012, intangible assets and accumulated intangible assets were comprised of the following:

	2013			2012
Intangible assets	$	54,719,918		$	25,702,909
Accumulated amortization		(8,511,833	)		(5,216,117	)
Intangible assets, net	$	46,208,085		$	20,486,792

Amortization of intangible assets for periods subsequent to December 31, 2013 is as follows:

Year Ended	Amortization
December 31,	Expense
2014	$	5,472,123
2015		5,472,123
2016		5,472,123
2017		5,472,123
Thereafter		24,319,593
Total	$	46,208,085

Equity (Tables)

12 Months Ended

Dec. 31, 2013

Equity [Abstract]

Activity related to warrants

BioTime has issued warrants to purchase its common shares. Activity related to warrants in 2013, 2012, and 2011 is presented in the table below:

	Number of Warrants			Per share exercise price		Weighted Average Exercise Price
Outstanding, January 1, 2011		649,000		$	0.68 - 10.00	$	6.42
Granted in 2011		206,613			10.00		10.00
Exercised in 2011		(219,000	)		0.68 - 3.00		1.94
Outstanding, December 31, 2011		636,613		$	3.00 – 10.00	$	9.13
Expired in 2012		(80,000	)		3.00		3.00
Outstanding, December 31, 2012		556,613		$	10.00	$	10.00
Granted in 2013		9,195,002			5.00		5.00
Outstanding, December 31, 2013		9,751,615		$	5.00 – 10.00	$	5.29

Summary of stock option activity for subsidiaries

A summary of all option activity under the subsidiary option plans (see Note 10) for the years ended December 31, 2013, 2012, and 2011 is as follows:

	Options Available for Grant			Number of Options Outstanding			Weighted Average Exercise Price
January 1, 2011		7,703,060			4,312,640		$	0.74
Added upon adoption of option plan in 2011		8,000,000			-			-
Granted in 2011		(4,685,000	)		4,685,000			0.36
Forfeited/Exercised in 2011		200,000			(200,000	)		0.05
December 31, 2011		11,218,060			8,797,640		$	0.56
Reverse stock split and change in plan in 2012		(3,697,014	)		(2,460,717	)		-
Granted in 2012		(1,479,490	)		1,479,490			1.39
Forfeited/Exercised in 2012		-			-			-
December 31, 2012		6,041,556			7,816,413		$	0.93
Increase option pool		500,000			-			-
Granted in 2013		(4,434,995	)		4,434,995			2.11
Expired/Forfeited/Exercised in 2013		785,000			(785,000	)		1.95
December 31, 2013		2,891,561			11,466,408		$	1.32

Allocation of stock based compensation expense

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References+ Details

Stock Option Plans (Tables)

12 Months Ended

Dec. 31, 2013

Stock Option Plans [Abstract]

	Year Ended December 31,
All stock-based compensation expense:	2013		2012		2011
Research and Development	$	829,938	$	815,052	$	885,581
General and Administrative		2,214,836		1,028,910		916,832
All stock-based compensation expense included in expenses	$	3,044,774	$	1,843,962	$	1,802,413

Schedule of weighted average assumptions to calculate fair value of stock options

	Year Ended December 31,
	2013			2012

Expected life (in years)		6.68			6.35
Risk-free interest rates		1.51	%		1.06	%
Volatility		95.22	%		98.88	%
Dividend yield		0	%		0	%

Summary of stock option activity

A summary of all option activity under the 2002 Plan and the 2012 Plan for the years ended December 31, 2013, 2012, and 2011, is as follows:

	Options Available for Grant			Number of Options Outstanding			Weighted Average Exercise Price
January 31, 2011		1,842,168			3,320,590		$	1.13
Granted under 2002 Plan		(560,443	)		560,443			4.89
Exercised		-			(450,660	)		0.50
Forfeited/expired		21,468			(21,468	)		5.60
December 31, 2011		1,303,193			3,408,905		$	2.18
Granted under 2002 Plan		(280,000	)		280,000			4.75
Granted under 2012 Plan		(255,000	)		255,000			3.45
Exercised		-			(98,541	)		2.91
Forfeited/expired under 2002 Plan		-			(164,063	)		5.60
Added by 2012 Plan⁽¹⁾		4,000,000			-			-
Reduce options ungranted under 2002 Plan⁽²⁾		(1,023,193	)		-			-
December 31, 2012		3,745,000			3,681,301		$	1.96
Granted under 2012 Plan		(1,585,000	)		1,585,000			4.13
Exercised		-			(20,000	)		2.30
Forfeited/expired under 2002 Plan		-			(524,166	)		4.01
Forfeited/expired under 2012 Plan		155,000			(155,000	)		4.18
December 31, 2013		2,315,000			4,567,135		$	2.71

1)	During December 2012, the 2012 Equity Incentive Plan was approved by the BioTime Board of Directors making 4,000,000 common shares available for the grant of options. This plan was approved by the shareholders during October 2013.

2)	During September 2012, the 2002 Plan expired.

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Additional information regarding options outstanding

Additional information regarding options outstanding as of December 31, 2013 is as follows:

			Options Outstanding				Options Exercisable

Range of Exercise Prices	Number Outstanding		Weighted Avg. Remaining Contractual Life (years)		Weighted Avg. Exercise Price		Number Exercisable		Weighted Avg. Exercise Price

$0.50		1,970,400		0.77	$	0.50		1,970,400	$	0.50
2.30-8.58		2,596,735		4.86		4.39		1,277,262		4.54
$0.50-$8.58		4,567,135		3.10	$	2.71		3,247,662	$	2.09

OncoCyte, OrthoCyte, ReCyte Therapeutics, Cell Cure Neurosciences, LifeMap and BioTime Asia [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Additional information regarding options outstanding

			Options Outstanding				Options Exercisable

Range of Exercise Prices	Number Outstanding		Weighted Avg. Remaining Contractual Life (years)		Weighted Avg. Exercise Price		Number Exercisable		Weighted Avg. Exercise Price

$0.003-$0.75		5,256,226		5.96	$	0.36		4,089,035	$	0.35
1.00-1.75		2,072,342		5.86		1.57		571,073		1.43
2.05-2.34		4,080,000		6.39		2.25		1,294,062		2.16
27.00-42.02		7,840		6.80		37.35		7,840		37.35
$0.003-$42.02		11,416,408		6.10	$	1.28		5,962,010	$	0.89

Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.

+ References+ Details

Asset Contribution Agreement [Abstract]

Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.

+ References+ Details

Asset Contribution Agreement (Tables)

12 Months Ended

Dec. 31, 2013

Assets Transferred by BioTime and Related Consideration

The assets transferred by BioTime and the related consideration paid were recorded as follows:

Consideration transferred to BioTime:
Asterias Series B shares	$	52,164,568
Warrants to purchase Asterias Series B shares		2,012,481
Excess of contributed assets’ value over consideration		4,800,063
Total consideration issued	$	58,977,112

Assets transferred by BioTime:
BioTime common shares, at fair value	$	34,985,163
BioTime Warrants, at fair value		18,276,406
Cancellation of outstanding obligation to BioTime		5,000,000
Investment in affiliates, at cost		415,543
Geron asset acquisition related transaction costs paid by BioTime		300,000
Total assets transferred	$	58,977,112

Assets Acquired from Geron and Related Consideration

The assets acquired from Geron and the related consideration were recorded as follows:

Consideration paid to Geron:
Asterias Series A shares, net of share issuance costs of $541,800	$	15,121,222
Obligation to distribute BioTime Warrants		18,276,406
Transaction and other costs		1,519,904
Total consideration paid	$	34,917,532
Assets acquired from Geron (preliminary allocation):
Patents and other intellectual property rights related to hES cells	$	29,017,009
Deferred tax liability arising from difference in book versus tax basis on Geron intangible assets acquired		(11,558,243	)
IPR&D expensed upon acquisition		17,458,766
Total assets and in-process research and development acquired	$	34,917,532

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2013

Income Taxes [Abstract]

Components of net deferred tax assets

The primary components of the net deferred tax liabillities at December 31, 2013 and 2012 were as follows:

	2013			2012
Deferred tax assets/(liabilities):
Net operating loss carryforwards	$	46,711,000		$	36,111,000
Research & development and other credits		2,329,000			1,856,000
Patents and licenses		(11,934,000	)		(1,066,000	)
Other, net		737,000			-
Total		37,843,000			36,901,000
Valuation allowance		(46,121,000	)		(36,901,000	)
Net deferred tax liabilities	$	(8,278,000	)	$	-

Income tax rate reconciliation

Income taxes differed from the amounts computed by applying the U.S. federal income tax of 34% to pretax losses from operations as a result of the following:

	Year Ended December 31,
	2013	2012	2011

Computed tax benefit at federal statutory rate	(34%)	(34%)	(34%)
Permanent differences	15%	3%	(1%)
Losses for which no benefit has been recognized	18%	28%	41%
State tax benefit, net of effect on federal income taxes	(4%)	-	(6%)
Foreign rate differential	(1%)	3%	-
	(6%)	0%	0%

Enterprise-wide Disclosures (Tables)

12 Months Ended

Dec. 31, 2013

Enterprise wide Disclosures [Abstract]

Geographic Area Information

Revenues, including license fees, royalties, grant income, and other revenues by geographic area are based on the country of domicile of the licensee or grantor.

Geographic Area	Revenues for the Year ending December 31,
	2013		2012		2011
Domestic	$	2,106,161	$	2,529,669	$	3,059,810
Asia		2,328,175		1,385,658		1,374,349
Total revenues	$	4,434,336	$	3,915,327	$	4,434,159

Sources of Revenues

Sources of Revenues	% of Total Revenues for Year ended December 31,
	2013			2012			2011
Hospira		6.5	%		11.0	%		14.2	%
CJ		1.7	%		2.9	%		3.5	%
Summit		20.3	%		3.7	%		3.3	%
CIRM		0.0	%		26.7	%		35.4	%
NIH		5.0	%		1.2	%		0.6	%
OCS		27.9	%		26.0	%		23.0	%
Subscription and Advertising (various customers)		38.6	%		28.5	%		20.0	%

Selected Quarterly Financial Information (UNAUDITED) [Abstract]

Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.

+ References+ Details

Selected Quarterly Financial Information (UNAUDITED) (Tables)

12 Months Ended

Dec. 31, 2013

Selected Quarterly Financial Information

20. Selected Quarterly Financial Information (UNAUDITED)

	First Quarter			Second Quarter			Third Quarter			Fourth Quarter
Year Ended December 31, 2013
Revenues, net	$	431,724		$	1,035,514		$	507,384		$	1,670,063
Acquired in-process research and development⁽¹⁾		-			-			-			17,458,766
Operating expenses		8,811,633			9,151,965			10,709,337			13,504,740
Loss from operations		(8,379,909	)		(8,116,451	)		(10,201,953	)		(29,293,443	)
Net loss attributable to BioTime, Inc.⁽²⁾		(7,719,263	)		(7,549,765	)		(9,003,168	)		(19,612,314	)

Basic and diluted net loss per share		(0.15	)		(0.14	)		(0.16	)		(0.35	)

Year Ended December 31, 2012
Revenues, net	$	631,946		$	949,746		$	833,817		$	1,065,547
Operating expenses		6,547,486			7,029,077			6,780,375			8,124,795
Loss from operations		(5,915,540	)		(6,079,331	)		(5,946,558	)		(7,059,248	)
Net loss attributable to BioTime, Inc.		(4,973,342	)		(5,457,222	)		(4,958,014	)		(6,037,125	)
Basic and diluted net loss per share		(0.10	)		(0.11	)		(0.10	)		(0.12	)

(1)	Includes IPR&D expenses related to intangible assets acquired by Asterias from Geron under the Asset Contribution Agreement. IPR&D represents the value of incomplete research and development projects which Asterias intends to continue. See Notes 2 and 15.

(2)	Net of $3,280,695 income tax benefits in fourth quarter.

Pro Forma Financial Information for Fiscal Years Ended December 31, 2013 and 2012 (UNAUDITED) (Tables)

12 Months Ended

Dec. 31, 2013

Pro Forma Financial Information for Fiscal Years Ended December 31, 2013 and 2012 (UNAUDITED)

Pro Forma Financial Information for Fiscal Years Ended December 31, 2013 and 2012

	Year Ended December 31,
	2013			2012

Revenues	$	4,434,336		$	4,206,973
(Loss) available to common shareholders⁽¹⁾	$	(26,424,069	)	$	(38,781,953	)
(Loss) per common share – basic	$	(0.49	)	$	(0.78	)
(Loss) per common share – diluted	$	(0.49	)	$	(0.78	)

(1)	For 2012, includes $17,458,766 of IPR&D acquired under the Asset Contribution Agreement which was completed on October 1, 2013. See Note 15.

Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.

Noncontrolling Interest [Line Items]

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1392-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1486-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141

-Paragraph 52

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141

-Paragraph 51

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141R

-Paragraph F4

-Subparagraph e

-Appendix F

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141R

-Paragraph 68

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Organization and Basis of Presentation (Details)

12 Months Ended

Dec. 31, 2013

Area

Dec. 31, 2013

Asterias Biotherapeutics, Inc. [Member]

Dec. 31, 2013

ReCyte Therapeutics, Inc. [Member]

Dec. 31, 2013

OncoCyte Corporation [Member]

Dec. 31, 2013

OrthoCyte Corporation [Member]

Dec. 31, 2013

ES Cell International Pte., Ltd. [Member]

Dec. 31, 2013

BioTime Asia, Limited [Member]

Dec. 31, 2013

Cell Cure Neurosciences, Ltd. [Member]

Dec. 31, 2013

LifeMap Sciences, Inc. [Member]

Dec. 31, 2013

LifeMap Sciences, Ltd. [Member]

Dec. 31, 2013

BioTime Acquisition Corporation [Member]

Oct. 01, 2013

BioTime Acquisition Corporation [Member]

Number areas which entity engaged in biomedical research and product development

BioTime Ownership (in hundredths)

71.60%

^[1]

94.80%

75.00%

100.00%

81.00%

62.50%

0.00%

^[2]

96.70%

71.60%

[1]	BioTime’s percentage ownership was reduced from approximately 96.7% to approximately 71.6% on October 1, 2013 when Asterias issued common stock to BioTime and Geron Corporation pursuant to an Asset Contribution Agreement and sold common stock and warrants to a private investor for cash in a related transaction.
[2]	LifeMap Sciences, Ltd. is a wholly-owned subsidiary of LifeMap Sciences, Inc.

Summary of Significant Accounting Policies (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Summary of Significant Accounting Policies [Abstract]
Trade receivable	$ 575,900	$ 395,000
Grants receivable	539,300	1,059,000
Allowance for doubtful accounts	116,816	116,816
Property, Plant and Equipment [Line Items]
Foreign currency gain (loss) included in comprehensive loss	119,469	63,179	(1,020,087)
Foreign currency transaction gain (loss)	$ 133,479	$ 34,233
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares excluded from computation of diluted loss per share (in shares)	4,567,135	3,681,301	3,408,905
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares excluded from computation of diluted loss per share (in shares)	9,751,615	556,613	636,613
Treasury Shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares excluded from computation of diluted loss per share (in shares)	10,697,715	1,800,109	1,286,174
Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Equipment useful life	36 months
Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Equipment useful life	120 months

Inventory (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Inventory [Abstract]
Inventory of finished products on-site	$ 165,771	$ 41,494
Inventory held by third party on consignment	$ 12,923	$ 13,822

Gross amount of inventory owned by the entity but in the hands of a customer, typically a reseller.

+ References+ Details

Equipment (Details) (USD $)	12 Months Ended
Equipment (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Equipment, furniture and fixtures [Abstract]
Equipment, furniture and fixtures	$ 4,431,586	$ 2,098,812
Accumulated depreciation	(1,433,853)	(750,258)
Equipment net of accumulated depreciation	2,997,733	1,348,554
Depreciation expense	656,759	386,457	373,349
Increase in accumulated depreciation	683,595
Write off fully depreciated assets offset by foreign currency rates	$ 1,500

The cumulative amount of depreciation, depletion and amortization (related to property, plant and equipment, but not including land) that has been recognized in the income statement.

+ References+ Details

The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.

+ References+ Details

Gross amount of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.

+ References+ Details

Amount, net of accumulated depreciation, depletion and amortization, of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.

+ References+ Details

Intangible assets (Details) (USD $)	12 Months Ended
Intangible assets (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Intangible assets, net [Abstract]
Intangible assets	$ 54,719,918	$ 25,702,909
Accumulated amortization	(8,511,833)	(5,216,117)
Intangible assets, net	46,208,085	20,486,792
Intangible assets, useful life	10 years
Amortization of intangible assets	3,295,716	2,446,975	1,991,200
Intangible assets future amortization expense [Abstract]
2014	5,472,123
2015	5,472,123
2016	5,472,123
2017	5,472,123
Thereafter	24,319,593
Intangible assets, net	$ 46,208,085	$ 20,486,792

Royalty Obligation and Deferred License Fees (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful life	10 years
Amortization of deferred license fees [Abstract]
2014	$ 111,000
2015	111,000
2016	111,000
2017	111,000
Thereafter	111,833
Total	555,833
Prepaid expenses in other current assets	111,000
Deferred license and consulting fees in noncurrent assts	444,833
WARF [Member]
Finite-Lived Intangible Assets [Line Items]
License agreement amount	225,000
Amended license agreement amount	295,000
Licensing fees paid	225,000
Common shares issued, market value	70,000
Remaining cash license fee amount	215,000
Fees for filing prosecuting and maintaining patent protection	20,000
Annual license maintenance fee	25,000
WARF [Member] \| Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Royalty rate on sale of products and services (in hundredths)	2.00%
WARF [Member] \| Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Royalty rate on sale of products and services (in hundredths)	4.00%
Advanced Cell Technology, Inc. [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful life	20 years
Royalty rate on sale of products and services (in hundredths)	8.00%
Licensing fees paid	250,000
Maximum royalty payments	1,000,000
Advanced Cell Technology Inc, with Kirin Sublicense I [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful life	20 years
Royalty rate on sale of products and services (in hundredths)	5.00%
Licensing fees paid	200,000
Maximum royalty payments	600,000
Fees for sublicense (in hundredths)	20.00%
Advanced Cell Technology Inc., with Kirin Sublicense II [Member]
Finite-Lived Intangible Assets [Line Items]
Royalty rate on sale of products and services (in hundredths)	3.50%
Licensing fees paid	50,000
Fees for sublicense (in hundredths)	20.00%
Annual minimum royalty due	50,000
Reproductive Genetics Institute [Member]
Finite-Lived Intangible Assets [Line Items]
Common shares issued, market value	50,000
Common shares issued (in shares)	32,259
Sanford-Burnham Medical Research Institute [Member]
Finite-Lived Intangible Assets [Line Items]
Fees for sublicense (in hundredths)	20.00%
Reduction in royalties payable, percentage (in hundredths)	50.00%
Portion of fees for filing, prosecuting, and maintaining patent protection to be reimbursed by subsidiary (in hundredths)	25.00%
Sanford-Burnham Medical Research Institute [Member] \| Pharmaceutical Products [Member]
Finite-Lived Intangible Assets [Line Items]
Royalty rate on sale of products and services (in hundredths)	4.00%
Sanford-Burnham Medical Research Institute [Member] \| Research Use Products [Member]
Finite-Lived Intangible Assets [Line Items]
Royalty rate on sale of products and services (in hundredths)	10.00%
Hadasit Medical Research Services and Development Ltd [Member]
Finite-Lived Intangible Assets [Line Items]
Royalty rate on sale of products and services (in hundredths)	5.00%
Annual minimum royalty due	100,000
Payment for patent expense	249,058
Payment to licensor upon exercise of option to license (in hundredths)	30.00%
Hadasit Medical Research Services and Development Ltd [Member] \| Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Fees for sublicense (in hundredths)	10.00%
Hadasit Medical Research Services and Development Ltd [Member] \| Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Fees for sublicense (in hundredths)	30.00%
Hadasit Medical Research Services and Development Ltd (Clinical trial phase I) [Member]
Finite-Lived Intangible Assets [Line Items]
Payments for attaining milestone	250,000
Hadasit Medical Research Services and Development Ltd (Clinical trial phase II) [Member]
Finite-Lived Intangible Assets [Line Items]
Payments for attaining milestone	250,000
Hadasit Medical Research Services and Development Ltd (Clinical trial phase III) [Member]
Finite-Lived Intangible Assets [Line Items]
Payments for attaining milestone	1,000,000
University of Utah License [Member]
Finite-Lived Intangible Assets [Line Items]
Royalty rate on sale of products and services (in hundredths)	3.00%
Fees for sublicense (in hundredths)	30.00%
Payments for attaining milestone	5,000
Minimum royalty amount in 2014	2,500
Minimum royalty amount in 2015 and thereafter	30,000
Number of licensed patents issued that trigger payments to licensor	5
University of Utah License [Member] \| Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Payments for attaining milestone	2,500
Number of other licensees that triggers reduction in payments for attaining milestone	2
University of Utah License, Milestone I [Member]
Finite-Lived Intangible Assets [Line Items]
Payments for attaining milestone	225,000
Sponsored Research Agreement with Weill Cornell Medical College [Member]
Finite-Lived Intangible Assets [Line Items]
Research period	3 years
Asterias License from the University of California [Member]
Finite-Lived Intangible Assets [Line Items]
Royalty rate on sale of products and services (in hundredths)	1.00%
Annual minimum royalty due	5,000
Maximum reduction in royality payments (in hundredths)	50.00%
Period of notice for termination of the agreement	60 days
Asterias Sublicenes from Geron [Member]
Finite-Lived Intangible Assets [Line Items]
Royalty rate on sale of products and services (in hundredths)	1.00%
Licensing fees paid	65,000
Annual license maintenance fee	$ 10,000
Period of notice for termination of the agreement	90 days

Accounts Payable and Accrued Liabilities (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Accounts Payable and Accrued Liabilities [Abstract]
Accounts payable	$ 3,887,950	$ 1,168,077
Accrued bonuses	600,000	497,843
Other accrued liabilities	2,234,674	2,324,042
Accounts payable and accrued liabilities	$ 6,722,624	$ 3,989,962

Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 7

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6911-107765

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 8

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References+ Details

Related Party Transactions (Details) (USD $)	12 Months Ended
Related Party Transactions (Details) (USD $)	Dec. 31, 2013 sqft
Related Party Transaction [Line Items]
Rent per month	$ 5,050
Area of office space (in square feet)	900
Number of warrants issued (in shares)	8,000,000
Cell Cure Neurosciences, Ltd. [Member]
Related Party Transaction [Line Items]
Number of shares purchased (in shares)	87,456
BioTime Acquisition Corporation [Member]
Related Party Transaction [Line Items]
Shares issued in exchange of shares purchase (in shares)	906,735
Stock issued during period (in shares)	8,902,077
Number of warrants issued (in shares)	8,000,000

The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References+ Details

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of new stock issued during the period.

+ References+ Details

Equity, Warrants and Options (Details) (USD $)	12 Months Ended
Equity, Warrants and Options (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
OncoCyte, OrthoCyte, ReCyte Therapeutics, Cell Cure Neurosciences, LifeMap and BioTime Asia [Member]
Options Available for Grant [Rollforward]
Beginning of the period (in shares)	6,041,556	11,218,060	7,703,060
Added upon adoption of option plan (in shares)			8,000,000
Reverse stock split and change in plan (in shares)		(3,697,014)
Increase option pool (in shares)	500,000
Granted (in shares)	(4,434,995)	(1,479,490)	(4,685,000)
Forfeited/Exercised (in shares)	785,000	0	200,000
End of the period (in shares)	2,891,561	6,041,556	11,218,060
Number of Options Outstanding [Rollforward]
Outstanding, beginning of the period (in shares)	7,816,413	8,797,640	4,312,640
Added upon adoption of option plan (in shares)			0
Reverse stock split and change in plan (in shares)		(2,460,717)
Increase option pool (in shares)	0
Granted (in shares)	4,434,995	1,479,490	4,685,000
Forfeited/Exercised (in shares)	(785,000)	0	(200,000)
Outstanding, end of the period (in shares)	11,466,408	7,816,413	8,797,640
Weighted Average Exercise Price [Rollforward]
Outstanding, beginning of the period (in dollars per share)	$ 0.93	$ 0.56	$ 0.74
Added upon adoption of option plan (in dollars per shares)			$ 0
Reverse stock split and change in plan (in dollars per share)		$ 0
Increase option pool (in dollars per share)	$ 0
Granted (in dollars per share)	$ 2.11	$ 1.39	$ 0.36
Forfeited/Exercised (in dollars per share)	$ 1.95	$ 0	$ 0.05
Outstanding end of the period (in dollars per share)	$ 1.32	$ 0.93	$ 0.56
Warrant [Member]
Numbers of Warrants [Roll Forward]
Warrants Outstanding Beginning Balance (in shares)	556,613	636,613	649,000
Granted (in shares)	9,195,002		206,613
Exercised (in shares)			(219,000)
Expired (in shares)		(80,000)
Warrants Outstanding Ending Balance (in shares)	9,751,615	556,613	636,613
Per share exercise price [Abstract]
Outstanding Beginning Balance (in dollars per share)	$ 10.00
Granted (in dollars per share)	$ 5.00		$ 10.00
Expired (in dollars per share)		$ 3.00
Outstanding Ending Balance (in dollars per share)		$ 10.00
Weighted Average Exercise Price [Abstract]
Outstanding Beginning Balance (in dollars per share)	$ 10.00	$ 9.13	$ 6.42
Granted (in dollars per share)	$ 5.00		$ 10.00
Exercised (in dollars per share)			$ 1.94
Expired (in dollars per share)		$ 3.00
Outstanding Ending Balance(in dollars per share)	$ 5.29	$ 10.00	$ 9.13
Weighted average remaining contractual life	0 years 3 months 25 days	1 year 3 months 25 days	1 year 8 months 5 days
Warrant [Member] \| Minimum [Member]
Per share exercise price [Abstract]
Outstanding Beginning Balance (in dollars per share)			$ 0.68
Exercised (in dollars per share)			$ 0.68
Outstanding Ending Balance (in dollars per share)	$ 5.00		$ 3.00
Warrant [Member] \| Maximum [Member]
Per share exercise price [Abstract]
Outstanding Beginning Balance (in dollars per share)			$ 10.00
Exercised (in dollars per share)			$ 3.00
Outstanding Ending Balance (in dollars per share)	$ 10.00		$ 10.00

Equity, Preferred and Common Shares (Details) (USD $)	12 Months Ended
Equity, Preferred and Common Shares (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Oct. 01, 2013	May 31, 2013
Preferred Shares [Abstract]
Preferred shares, shares authorized (in shares)	2,000,000	1,000,000		1,000,000
Preferred shares, issued and outstanding (in shares)	0	0
Common Shares [Abstract]
Common shares, authorized (in shares)	125,000,000	75,000,000		75,000,000
Common shares, par value (in dollars per share)	$ 0	$ 0
Common shares, shares issued (in shares)	67,412,139	51,183,318
Common shares, shares outstanding (in shares)	56,714,424	49,383,209
Treasury stock (in shares)	10,697,715	1,800,109
Options exercised (in shares)		98,541
Gross proceeds from issuance of common shares	$ 22,297,209	$ 1,002,220
Cash received from investors	(5,255,502)	(250,000)
Exercised (in dollars per share)		$ 2.91
Proceeds from issuance of stock and warrants to private investor		286,552
Initial exercise price of unit (in dollars per share)			$ 5.00
Asterias Biotherapeutics [Member]
Common Shares [Abstract]
Stock issued during period (in shares)	8,902,077
Initial exercise price of unit (in dollars per share)	$ 5.00
Cell Cure Nuerosciences ,Ltd. [Member]
Common Shares [Abstract]
Number of shares purchased (in shares)	87,456
LifeMap Sciences, Inc. [Member]
Common Shares [Abstract]
Treasury stock (in shares)		513,935
Stock issued during period (in shares)		592,533
Market value of common shares issued		2,750,003
Cash received from investors		250,000
Shares received by subsidiary (in shares)		1,714,287
Sale of stock by subsidiary (in shares)		78,598
Proceeds from sale of stock by subsidiary		282,826
Merger of XenneX with LifeMap Sciences, Inc. [Member]
Common Shares [Abstract]
Stock issued during period (in shares)		448,429
BioTime Acquisition Corporation [Member]
Common Shares [Abstract]
Stock issued during period (in shares)	8,902,077
Number of shares issued in exchange for shares of The Company (in shares)	906,735
Warrants issued (in shares)	8,000,000
Landlord [Member]
Common Shares [Abstract]
Stock issued during period (in shares)	73,553
Market value of common shares issued	242,726
Value of common shares issued	253,758
Certain investors [Member]
Common Shares [Abstract]
Stock issued during period (in shares)	2,180,016
Gross proceeds from issuance of common shares	9,057,967
Warrants issued (in shares)	545,004
Number of shares in a unit (in shares)	1
Number of warrants in a unit (in shares)	0.025
Offering price of unit (in dollars per share)	$ 4.155
Initial exercise price of unit (in dollars per share)	$ 5.00
Life of warrants	5 years
Private Investors [Member]
Common Shares [Abstract]
Stock issued during period (in shares)	1,350,000
Gross proceeds from issuance of common shares	5,000,000
Warrants issued (in shares)	649,999
Cantor Fitzgerald Controlled Equity Offering [Member]
Common Shares [Abstract]
Stock issued during period (in shares)	3,665,646	314,386
Gross proceeds from issuance of common shares	15,722,339	1,131,279
Aggregate offering price	$ 25,000,000

Stock Option Plans (Details) (USD $)

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Total unrecognized compensation costs

$ 5,609,851

Weighted average recognition period

5 years 5 months 23 days

Weighted-average estimated fair value of stock options granted (in dollars per share)

$ 4.13

Weighted-average assumptions [Abstract]

Expected life (in years)

6 years 8 months 5 days

6 years 4 months 6 days

Risk-free interest rates (in hundredths)

1.51%

1.06%

Volatility (in hundredths)

95.22%

98.88%

Dividend yield (in hundredths)

0.00%

Exercised (in shares)

(98,541)

Exercised (in dollars per share)

$ 2.91

$0.50 [Member]

Additional Information regarding options outstanding [Abstract]

Range of Exercise Prices, Upper Range Limit (in dollars per share)

$ 0.50

Options Outstanding, Weighted Avg. Remaining Contractual Life

1,970,400

0 years 9 months 7 days

Options Outstanding, Weighted Average Exercise Price (in dollars per share)

$ 0.50

Options Exercisable, Weighted Average Exercise Price (in dollars per share)

1,970,400

$ 0.50

2.30-8.58 [Member]

Additional Information regarding options outstanding [Abstract]

Options Outstanding, Weighted Avg. Remaining Contractual Life

2,596,735

4 years 10 months 10 days

Options Outstanding, Weighted Average Exercise Price (in dollars per share)

$ 4.39

Options Exercisable, Weighted Average Exercise Price (in dollars per share)

1,277,262

$ 4.54

2.30-8.58 [Member] | Minimum [Member]

Additional Information regarding options outstanding [Abstract]

Range of Exercise Prices, Lower Range Limit (in dollars per share)

$ 2.30

2.30-8.58 [Member] | Maximum [Member]

Additional Information regarding options outstanding [Abstract]

Range of Exercise Prices, Upper Range Limit (in dollars per share)

$ 8.58

$0.50-$8.58 [Member]

Additional Information regarding options outstanding [Abstract]

Options Outstanding, Weighted Avg. Remaining Contractual Life

4,567,135

3 years 1 month 6 days

Options Outstanding, Weighted Average Exercise Price (in dollars per share)

$ 2.71

Options Exercisable, Weighted Average Exercise Price (in dollars per share)

3,247,662

$ 2.09

$0.50-$8.58 [Member] | Minimum [Member]

Additional Information regarding options outstanding [Abstract]

Range of Exercise Prices, Lower Range Limit (in dollars per share)

$ 0.50

$0.50-$8.58 [Member] | Maximum [Member]

Additional Information regarding options outstanding [Abstract]

Range of Exercise Prices, Upper Range Limit (in dollars per share)

$ 8.58

0.003-$0.75 [Member]

Additional Information regarding options outstanding [Abstract]

Options Outstanding, Weighted Avg. Remaining Contractual Life

5,256,226

5 years 11 months 16 days

Options Outstanding, Weighted Average Exercise Price (in dollars per share)

$ 0.36

Options Exercisable, Weighted Average Exercise Price (in dollars per share)

4,089,035

$ 0.35

0.003-$0.75 [Member] | Minimum [Member]

Additional Information regarding options outstanding [Abstract]

Range of Exercise Prices, Lower Range Limit (in dollars per share)

$ 0.003

0.003-$0.75 [Member] | Maximum [Member]

Additional Information regarding options outstanding [Abstract]

Range of Exercise Prices, Upper Range Limit (in dollars per share)

$ 0.75

1.00-1.75 [Member]

Additional Information regarding options outstanding [Abstract]

Options Outstanding, Weighted Avg. Remaining Contractual Life

2,072,342

5 years 10 months 10 days

Options Outstanding, Weighted Average Exercise Price (in dollars per share)

$ 1.57

Options Exercisable, Weighted Average Exercise Price (in dollars per share)

571,073

$ 1.43

1.00-1.75 [Member] | Minimum [Member]

Additional Information regarding options outstanding [Abstract]

Range of Exercise Prices, Lower Range Limit (in dollars per share)

$ 1.00

1.00-1.75 [Member] | Maximum [Member]

Additional Information regarding options outstanding [Abstract]

Range of Exercise Prices, Upper Range Limit (in dollars per share)

$ 1.75

2.05 [Member]

Additional Information regarding options outstanding [Abstract]

Range of Exercise Prices, Upper Range Limit (in dollars per share)

$ 2.05

Options Outstanding, Weighted Avg. Remaining Contractual Life

4,080,000

6 years 4 months 20 days

Options Outstanding, Weighted Average Exercise Price (in dollars per share)

$ 2.25

Options Exercisable, Weighted Average Exercise Price (in dollars per share)

1,294,062

$ 2.16

27.00-42.02 [Member]

Additional Information regarding options outstanding [Abstract]

Options Outstanding, Weighted Avg. Remaining Contractual Life

7,840

6 years 9 months 18 days

Options Outstanding, Weighted Average Exercise Price (in dollars per share)

$ 37.35

Options Exercisable, Weighted Average Exercise Price (in dollars per share)

7,840

$ 37.35

27.00-42.02 [Member] | Minimum [Member]

Additional Information regarding options outstanding [Abstract]

Range of Exercise Prices, Lower Range Limit (in dollars per share)

$ 27.00

27.00-42.02 [Member] | Maximum [Member]

Additional Information regarding options outstanding [Abstract]

Range of Exercise Prices, Upper Range Limit (in dollars per share)

$ 42.02

0.003-$42.02 [Member]

Additional Information regarding options outstanding [Abstract]

Options Outstanding, Weighted Avg. Remaining Contractual Life

11,416,408

6 years 1 month 6 days

Options Outstanding, Weighted Average Exercise Price (in dollars per share)

$ 1.28

Options Exercisable, Weighted Average Exercise Price (in dollars per share)

5,962,010

$ 0.89

0.003-$42.02 [Member] | Minimum [Member]

Additional Information regarding options outstanding [Abstract]

Range of Exercise Prices, Lower Range Limit (in dollars per share)

$ 0.003

0.003-$42.02 [Member] | Maximum [Member]

Additional Information regarding options outstanding [Abstract]

Range of Exercise Prices, Upper Range Limit (in dollars per share)

$ 42.02

2002 Plan and 2012 Plan [Member]

Options Available for Grant [Rollforward]

Beginning of the period (in shares)

3,745,000

1,303,193

1,842,168

(1,585,000)

Exercised (in shares)

End of the period (in shares)

21,468

2,315,000

3,745,000

1,303,193

Outstanding, beginning of the period (in shares)

3,681,301

3,408,905

3,320,590

1,585,000

Exercised (in shares)

(20,000)

(98,541)

(450,660)

Outstanding, end of the period (in shares)

(21,468)

4,567,135

3,681,301

3,408,905

Outstanding, beginning of the period (in dollars per share)

$ 1.96

$ 2.18

$ 1.13

Granted (in dollars per share)

$ 4.13

Exercised (in dollars per share)

$ 2.30

$ 2.91

$ 0.50

Forfeited/expired (in dollars per share)

$ 5.60

Outstanding end of the period (in dollars per share)

$ 2.71

$ 1.96

$ 2.18

2002 Plan [Member]

Options Available for Grant [Rollforward]

(280,000)

(560,443)

Reduce options ungranted under 2002 Plan (in shares)

(1,023,193)

^[1]

280,000

560,443

Reduce options ungranted under 2002 Plan (in shares)

(524,166)

(164,063)

^[1]

Granted (in dollars per share)

$ 4.75

$ 4.89

Forfeited/expired (in dollars per share)

$ 4.01

$ 5.60

Reduce options ungranted under 2002 Plan (in dollars per share)

$ 0

^[1]

2012 Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Common shares reserved for future issuance (in shares)

4,000,000

Period when options may not be granted or exercised

10 years

Options Available for Grant [Rollforward]

(255,000)

Added by 2012 Plan (in shares)

155,000

4,000,000

^[2]

255,000

Added by 2012 Plan (in shares)

(155,000)

^[2]

Granted (in dollars per share)

$ 3.45

Forfeited/expired (in dollars per share)

$ 4.18

Added by 2012 Plan (in dollars per share)

$ 0

^[2]

OncoCyte, OrthoCyte and ReCyte Therapeutics stock option plans [Member]

Additional Information regarding options outstanding [Abstract]

Authorize number of shares under stock option plan (in shares)

4,000,000

BioTime Asia stock option plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of options to purchase for employees (in shares)

4,500,000

Additional Information regarding options outstanding [Abstract]

Authorize number of shares under stock option plan (in shares)

14,100

Cell Cure Neurosciences' option plan [Member]

Additional Information regarding options outstanding [Abstract]

Authorize number of shares under stock option plan (in shares)

1,600

Granted under 2012 Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of options to purchase for employees (in shares)

4,000,000

Lifemap Stock Option Plan [Member]

Additional Information regarding options outstanding [Abstract]

Authorize number of shares under stock option plan (in shares)

8,000,000

Asterias Equity Incentive Plan [Member]

50,000

[1]	During September 2012, the 2002 Plan expired.
[2]	During December 2012, the 2012 Equity Incentive Plan was approved by the BioTime Board of Directors making 4,000,000 common shares available for the grant of options. This plan was approved by the shareholders during October 2013.

Stock Option Plans, Allocation of Recognized Period Costs (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
All stock-based compensation expense [Abstract]
Stock-based compensation expense	$ 3,044,774	$ 1,843,962	$ 1,802,413
Research and Development [Member]
All stock-based compensation expense [Abstract]
Stock-based compensation expense	829,938	815,052	885,581
General and Administrative [Member]
All stock-based compensation expense [Abstract]
Stock-based compensation expense	$ 2,214,836	$ 1,028,910	$ 916,832

Selected Quarterly Financial Information [Abstract]

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References+ Details

Cell Targeting, Inc Asset Purchase (Details) (Cell Targeting, Inc. [Member], USD $)	0 Months Ended	12 Months Ended
	Jan. 28, 2011	Dec. 31, 2013	Dec. 31, 2011
Cell Targeting, Inc. [Member]
Business Acquisition [Line Items]
Date of acquisition		Jan. 28, 2011
Number of shares issued as part of acquisition (in shares)	261,959
Intangible assets, useful life		10 years
Components of the purchase price [Abstract]
BioTime common shares	$ 2,300,000
Cash	250,000
Total purchase price	2,550,000
Assets acquired and liabilities assumed [Abstract]
Cash	3,150
Other current assets	2,443
Due from sellers	593,353
Intangible assets	2,419,287
Current liabilities	(468,233)
Net assets acquired	$ 2,550,000
Fair value share issued (in dollars per share)	$ 8.78
Number of trading days preceding the agreement used for share price calculation			20 days

Merger with Glycosan BioSystems, Inc (Details) (Merger with Glycosan BioSystems, Inc. [Member], USD $)	0 Months Ended	12 Months Ended
	Mar. 21, 2011	Dec. 31, 2013	Dec. 31, 2011	Mar. 18, 2011
Merger with Glycosan BioSystems, Inc. [Member]
Business Acquisition [Line Items]
Date of acquisition		Mar. 21, 2011
Assumed obligations				$ 252,000
Number of shares issued as part of acquisition (in shares)	332,903
Warrants issued to purchase common shares (in shares)	206,613
Intangible assets, useful life			10 years
Components of the purchase price [Abstract]
BioTime common shares	2,600,000
BioTime warrants	954,879
Total purchase price	3,554,879
Assets acquired and liabilities assumed [Abstract]
Cash	5,908
Other current assets	64,520
Property, plant and equipment, net	81,183
Intangible assets	3,592,039
Current liabilities	(188,771)
Net assets acquired	$ 3,554,879
Fair value share issued (in dollars per share)	$ 7.81
Number of trading days preceding the agreement used for share price calculation			10 days
Expected term	3 years
Risk-free interest rates (in hundredths)	1.12%
Expected dividend yield (in hundredths)	0.00%
Expected volatility (in hundredths)	109.01%
Stock price (in dollars per share)	$ 7.56
Exercise price (in dollars per share)	$ 10

Merger with XenneX, Inc (Details) (Merger with XenneX, Inc. [Member], USD $)	12 Months Ended
	Dec. 31, 2013	May 18, 2012
Business Acquisition [Line Items]
Liabilities assumed		$ 572,826
Intangible assets, useful life	10 years
Components of the purchase price [Abstract]
Total purchase price		4,304,099
Assets acquired and liabilities assumed [Abstract]
Cash		292,387
Other current assets		311,118
Intangible assets		4,273,420
Current liabilities		(294,572)
Cash distributable to sellers		(278,254)
Net assets acquired		4,304,099
Fair value of shares issued (in dollar per share)		$ 4.02
LifeMap Sciences, Inc. [Member]
Business Acquisition [Line Items]
Equity interests issued (in shares)	1,429,380
Subsequent Event, Percentage of Common Shares Outstanding Issued in Transaction (in hundredths)	13.70%
Components of the purchase price [Abstract]
Common shares		2,501,415
Assets acquired and liabilities assumed [Abstract]
Fair value of shares issued (in dollar per share)		$ 1.75
BioTime, Inc. [Member]
Business Acquisition [Line Items]
Equity interests issued (in shares)	448,429
Components of the purchase price [Abstract]
Common shares		$ 1,802,684

Share Exchange and Contribution Agreement (Details) (USD $)			1 Months Ended		12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2012 Share Exchange and Contribution Agreement [Member]	Jul. 31, 2012 Share Exchange and Contribution Agreement [Member]	Dec. 31, 2012 Share Exchange and Contribution Agreement [Member]	Jul. 24, 2012 Share Exchange and Contribution Agreement [Member]
Subsidiary or Equity Method Investee [Line Items]
Minimum value of common shares contributed						$ 2,000,000
Maximum value of common shares contributed						3,000,000
Initial per share price (in dollars per share)						$ 1.75
Common shares contributed (in shares)			172,533	420,000
Number of common shares received in exchange for capital contribution (in shares)			427,566	1,143,864
Number of trading days considered for weighted average closing price				10 days
Sale of subsidiary stock (in shares)					142,857
Original ownership interest percentage in LifeMap (in hundredths)			86.30%		86.30%
New ownership interest percentage (in hundredths)			73.20%		73.20%
Treasury stock (in shares)	10,697,715	1,800,109	513,935		513,935
Treasury stock value	43,033,957	8,375,397	2,375,397		2,375,397
Percentage of ownership in subsidiary permitted to party under agreement (in hundredths)					3.75%
Stock issued during period shares under agreement by subsidiary (in shares)					66,791
Stock issued during period value under agreement by subsidiary					$ 117,000

Asset Contribution Agreement (Details) (USD $)	0 Months Ended	12 Months Ended
Asset Contribution Agreement (Details) (USD $)	Oct. 01, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Asset Contribution Agreement [Line Items]
Common shares, par value (in dollars per share)		$ 0	$ 0
Number of warrants issued (in shares)		8,000,000
Number of warrants to be issued by Asterias to Series A common shareholders (in shares)		8,000,000
Exercise price of warrant (in dollars per share)	$ 5.00
Proceeds from issuance of common shares	$ 5,000,000	$ 25,938,558	$ 1,131,279	$ 0
Transaction costs allocated to issuance of equity		541,800
Intangible assets, useful life		10 years
Weighted-average assumptions [Abstract]
BioTIme common shares, at fair value		34,985,163	0	0
BioTime Warrants, at fair value		18,276,406	0	0
Common [Member]
Asset Contribution Agreement [Line Items]
Market value of BioTime common stock (in dollars per share)	$ 3.93
Common Class A [Member]
Asset Contribution Agreement [Line Items]
Common shares, par value (in dollars per share)		$ 0.0001
Common Class B [Member]
Asset Contribution Agreement [Line Items]
Common shares, par value (in dollars per share)		$ 0.0001
Warrants [Member]
Weighted-average assumptions [Abstract]
Expected term	5 years
Risk-free interest rate (in hundredths)	1.42%
Dividend yield (in hundredths)	0.00%
Expected volatility (in hundredths)	77.63%
Asterias Biotherapeutics [Member]
Asset Contribution Agreement [Line Items]
Stock issued during period (in shares)		8,902,077
Number of warrants issued (in shares)		8,000,000
Exercise price of warrant (in dollars per share)		$ 5.00
Warrant expiration term		5 years
Amount of contribution from investor		5,000,000
Weighted-average assumptions [Abstract]
Asterias Series B shares	52,164,568
Warrants to purchase Asterias Series B shares	2,012,481
Excess of contributed asset's value over consideration	4,800,063
Total consideration issued	58,977,112
BioTIme common shares, at fair value	34,985,163
BioTime Warrants, at fair value	18,276,406
Cancellation of outstanding obligation to BioTime	5,000,000
Investment in affiliates, at cost	415,543
Geron asset acquisition related transaction costs paid by BioTime	300,000
Total assets transferred	58,977,112
Asterias Biotherapeutics [Member] \| Common Class B [Member]
Asset Contribution Agreement [Line Items]
Stock issued during period (in shares)		21,773,340
Number of warrants issued (in shares)		3,150,000
Exercise price of warrant (in dollars per share)		$ 5.00
Warrant expiration term		3 years
Fair value of shares issued (in dollars per share)		$ 2.40
Weighted-average assumptions [Abstract]
Expected term		3 years
Risk-free interest rate (in hundredths)		0.63%
Dividend yield (in hundredths)		0.00%
Expected volatility (in hundredths)		69.62%
OrthoCyte Corporation [Member]
Asset Contribution Agreement [Line Items]
Percentage of subsidiary stock contributed (in hundredths)		10.00%
Cell Cure Neurosciences, Ltd. [Member]
Asset Contribution Agreement [Line Items]
Percentage of subsidiary stock contributed (in hundredths)		6.00%
Geron [Member]
Weighted-average assumptions [Abstract]
Total consideration issued	34,917,532
Asterias Series A shares, net of issuance cost of $541,800	15,121,222
Obligation to distribute BioTIme Warrants	18,276,406
Transaction and other costs	1,519,904
Patents and other intellectual property rights related to hES cells, asset contribution agreement	29,017,009
Deferred tax liability arising from difference in book versus tax basis on Geron intangible assets acquired	(11,588,243)
IPR&D expensed upon acquisition	17,458,766
Total assets and in-process research and development acquired	$ 34,917,532
Geron [Member] \| Common Class A [Member]
Asset Contribution Agreement [Line Items]
Stock issued during period (in shares)		6,537,779
Royalty rate on net sales of products (in hundredths)		4.00%
Romulus Films, Ltd. [Member] \| Common Class B [Member]
Asset Contribution Agreement [Line Items]
Stock issued during period (in shares)	2,136,000
Number of warrants issued (in shares)	350,000

Commitments and Contingencies (Details)	12 Months Ended				12 Months Ended		12 Months Ended
Commitments and Contingencies (Details)	Dec. 31, 2013 USD ($)	Dec. 31, 2012 USD ($)	Dec. 31, 2011 USD ($)	Dec. 31, 2013 BioTime [Member] Office and research laboratory in Alameda [Member] USD ($)	Dec. 31, 2013 BioTime [Member] Office and research facility in La Jolla [Member] USD ($)	Dec. 31, 2013 BioTime [Member] Office space in New York City [Member] USD ($)	Dec. 31, 2013 Asterias Biotherapeutics, Inc. [Member] Office and research facility in Menlo Park [Member] USD ($)	Dec. 31, 2013 Asterias Biotherapeutics, Inc. [Member] Office and research facility in Fremont [Member] USD ($) sqft	Dec. 31, 2013 ESI [Member] Laboratory space [Member] USD ($) sqm	Dec. 31, 2013 ESI [Member] Laboratory space [Member] SGD	Dec. 31, 2013 LifeMap Sciences, Inc. [Member] Office space in Tel Aviv, Israel [Member] USD ($)	Dec. 31, 2013 LifeMap Sciences, Inc. [Member] Office space in Tel Aviv, Israel [Member] ILS	Dec. 31, 2013 LifeMap Sciences, Inc. [Member] Office space in Hong Kong [Member] USD ($)	Dec. 31, 2013 LifeMap Sciences, Inc. [Member] Office space in Hong Kong [Member] HKD	Dec. 31, 2013 LifeMap Sciences, Inc. [Member] Office space in Marshfield, Massachusetts [Member] USD ($)	Dec. 31, 2013 Cell Cure Neurosciences, Ltd. [Member] Office and laboratory space, Jerusalem, Israel [Member] USD ($) sqm	Dec. 31, 2013 Cell Cure Neurosciences, Ltd. [Member] Office and laboratory space, Jerusalem, Israel [Member] ILS
Operating Leased Assets [Line Items]
Lease commencement date					Oct. 15, 2013		Jan. 07, 2013	Oct. 01, 2014					Dec. 01, 2013	Dec. 01, 2013
Lease Expiration Date									Feb. 28, 2014	Feb. 28, 2014	May 31, 2015	May 31, 2015	Nov. 30, 2015	Nov. 30, 2015	Sep. 30, 2015	Jun. 01, 2014	Jun. 01, 2014
Number of terms lease can be extended					1 year 0 months 14 days		3 years	96 months
Number of years lease can be extended (in years)																5 years	5 years
Leased area								44,000	125	125						290	290
Leased area during first 15 months (in square feet)								22,000
Base rent				$ 30,752	$ 4,330	$ 5,050	$ 31,786	$ 99,000	$ 8,700	11,000	$ 7,400	25,889	$ 970	7,500	$ 1,082	$ 9,500	33,000
Base rent increase rate (in hundredths)				3.00%				3.00%
Liable for improvement cost																236,000	820,000
Rent expenses	1,599,725	1,178,840	1,058,170
Real estate taxes during first 15 months								50.00%
Levied taxes on excess assessed valuation								100.00%
Minimum annual lease payments under the various operating leases [Abstract]
2014	1,188,316
2015	1,973,845
2016	1,266,825
2017	1,271,160
2018	1,308,120
Thereafter	5,262,840
Total	$ 12,271,106

Income Taxes (Details) (USD $)	12 Months Ended
Income Taxes (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Deferred tax assets/(liabilities) [Abstract]
Net operating loss carryforwards	$ 46,711,000	$ 36,111,000
Research & development and other credits	2,329,000	1,856,000
Patents and licenses	(11,934,000)	(1,066,000)
Other, net	737,000	0
Total	37,843,000	36,901,000
Valuation allowance	(46,121,000)	(36,901,000)
Net deferred tax (liabillities)	(8,278,000)	0
Income tax rate reconciliation [Abstract]
Computed tax benefit at federal statutory rate (in hundredths)	(34.00%)	(34.00%)	(34.00%)
Permanent differences (in hundredths)	15.00%	3.00%	(1.00%)
Losses for which no benefit has been recognized (in hundredths)	18.00%	28.00%	41.00%
State tax benefit, net of effect on federal income taxes (in hundredths)	(4.00%)	0.00%	(6.00%)
Research and development and other credits (in hundredths)	(1.00%)	3.00%	0.00%
Total (in hundredths)	(6.00%)	0.00%	0.00%
Net operating loss carryforwards for federal tax purposes	99,100,000
Net operating loss carryforwards for state tax purposes	70,200,000
Tax Credit Carryforward [Line Items]
Foreign net operating loss carryforwards	48,400,000
Deferred income tax benefit	3,280,695	0	0
Deferred federal income tax benefit	2,800,000
Deferred state income tax benefit	480,000
Percentage of change in ownership (in hundredths)	50.00%
Period in which change of ownership for a specified percentage should occur	3 years
Federal [Member]
Tax Credit Carryforward [Line Items]
Tax credit carryforwards	1,076,000
State [Member]
Tax Credit Carryforward [Line Items]
Tax credit carryforwards	$ 1,253,000

Enterprise-wide Disclosures (Details) (USD $)	1 Months Ended	12 Months Ended
Enterprise-wide Disclosures (Details) (USD $)	Feb. 28, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Apr. 30, 2009
Geographic Area [Abstract]
Domestic		$ 2,106,161	$ 2,529,669	$ 3,059,810
Asia		2,328,175	1,385,658	1,374,349
Total revenues		4,434,336	3,915,327	4,434,159
Revenue, Major Customer [Line Items]
Number of major customers		2
Number of major grants		2
Grants revenue		1,573,329	2,222,458	2,767,181
Hospira [Member]
Revenue, Major Customer [Line Items]
Percentage of total revenues (in hundredths)		6.50%	11.00%	14.20%
C J [Member]
Revenue, Major Customer [Line Items]
Percentage of total revenues (in hundredths)		1.70%	2.90%	3.50%
Summit [Member]
Revenue, Major Customer [Line Items]
Percentage of total revenues (in hundredths)		20.30%	3.70%	3.30%
C I R M [Member]
Revenue, Major Customer [Line Items]
Award granted from research project					4,721,706
Payment received from research project	392,664
Grants revenue		0	1,047,106
Percentage of total revenues (in hundredths)		0.00%	26.70%	35.40%
OCS [Member]
Revenue, Major Customer [Line Items]
Percentage of total revenues (in hundredths)		27.90%	26.00%	23.00%
Others [Member]
Revenue, Major Customer [Line Items]
Percentage of total revenues (in hundredths)		38.60%	28.50%	20.00%
N I H [Member]
Revenue, Major Customer [Line Items]
Award granted from research project		335,900
Remaining award granted from research project		110,237
Payment received from research project		111,691	45,645
Grants revenue		150,239	47,507
Percentage of total revenues (in hundredths)		5.00%	1.20%	0.60%
N I H, Separate Grant Awarded [Member]
Revenue, Major Customer [Line Items]
Grants revenue		71,355
Cell Cure Neurosciences, Ltd. [Member]
Revenue, Major Customer [Line Items]
Grants revenue		1,333,901	1,109,699
LifeMap Sciences, Ltd. [Member]
Revenue, Major Customer [Line Items]
Payment received from research project		1,082,077	1,222,516
Grants revenue		13,838
Advertising revenue		609,314	373,798
Revenues of royalty and commission fees		707,695	379,098
ESI [Member]
Revenue, Major Customer [Line Items]
Grants revenue		$ 3,996	$ 18,145

Selected Quarterly Financial Information (UNAUDITED) (Details) (USD $)

3 Months Ended

12 Months Ended

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Revenues, net

$ 1,670,063

$ 507,384

$ 1,035,514

$ 431,724

$ 1,065,547

$ 833,817

$ 949,746

$ 631,946

$ 4,434,336

$ 3,915,327

$ 4,434,159

Acquired in-process research and development

17,458,766

^[1]

17,458,766

Operating expenses

13,504,740

10,709,337

9,151,965

8,811,633

8,124,795

6,780,375

7,029,077

6,547,486

59,626,863

28,481,733

23,041,193

Loss from operations

(29,293,443)

(10,201,953)

(8,116,451)

(8,379,909)

(7,059,248)

(5,946,558)

(6,079,331)

(5,915,540)

(55,985,186)

(25,000,677)

(18,686,431)

Net loss attributable to BioTime, Inc.

$ (19,612,314)

^[2]

$ (9,003,168)

^[2]

$ (7,549,765)

^[2]

$ (7,719,263)

^[2]

$ (6,037,125)

$ (4,958,014)

$ (5,457,222)

$ (4,973,342)

$ (43,882,835)

$ (21,425,703)

$ (16,515,500)

Basic and diluted net loss per share (in dollars per share)

$ (0.35)

$ (0.16)

$ (0.14)

$ (0.15)

$ (0.12)

$ (0.10)

$ (0.11)

$ (0.10)

$ (0.81)

$ (0.44)

$ (0.35)

[1]	Includes IPR&D expenses related to intangible assets acquired by Asterias from Geron under the Asset Contribution. IPR&D represents the value of incomplete research and development projects which Asterias intends to continue. See Notes 2 and 15.
[2]	Net of $3,280,695 income tax benefits in fourth quarter.

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

Pro Forma Financial Information for Fiscal Years Ended December 31, 2013 and 2012 (UNAUDITED)

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Pro Forma Financial Information for Fiscal Years Ended December 31, 2013 and 2012 (UNAUDITED) (Details) (USD $)

3 Months Ended

12 Months Ended

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Revenues

$ 4,434,336

$ 4,206,973

(Loss) available to common shareholders

(26,424,069)

^[1]

(38,781,953)

^[1]

(Loss) per common share - basic (in dollars per share)

$ (0.49)

$ (0.78)

(Loss) per common share - diluted (in dollars per share)

$ (0.49)

$ (0.78)

Acquired in-process research and development

$ 17,458,766

^[2]

$ 0

^[2]

$ 0

^[2]

$ 0

^[2]

$ 17,458,766

$ 0

[1]	For 2012, includes $17,458,766 of IPR&D acquired under the Asset Contribution Agreement which was completed on October 1, 2013. See Note 15.
[2]	Includes IPR&D expenses related to intangible assets acquired by Asterias from Geron under the Asset Contribution. IPR&D represents the value of incomplete research and development projects which Asterias intends to continue. See Notes 2 and 15.

The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.

+ References+ Details